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A B S T R A C T
Background
People with Down syndrome are vulnerable to developing dementia at an earlier age than the general population. Alzheimer’s disease
and cognitive decline in people with Down syndrome can place a significant burden on both the person with Down syndrome and their
family and carers. Various pharmacological interventions, including donepezil, galantamine, memantine and rivastigmine, appear to
have some effect in treating cognitive decline in people without Down syndrome, but their effectiveness for those with Down syndrome
remains unclear.
Objectives
To assess the effectiveness of anti-dementia pharmacological interventions and nutritional supplements for treating cognitive decline
in people with Down syndrome.
Search methods
In January 2015, we searched CENTRAL, ALOIS (the Specialised Register of the Cochrane Dementia and Cognitive Improvement
Group), Ovid MEDLINE, Embase, PsycINFO, seven other databases, and two trials registers. In addition, we checked the references
of relevant reviews and studies and contacted study authors, other researchers and relevant drug manufacturers to identify additional
studies.
Selection criteria
Randomised controlled trials (RCTs) of anti-dementia pharmacological interventions or nutritional supplements for adults (aged 18
years and older) with Down syndrome, in which treatment was administered and compared with either placebo or no treatment.
Data collection and analysis
Two review authors independently assessed the risk of bias of included trials and extracted the relevant data. Review authors contacted
study authors to obtain missing information where necessary.
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Main results
Only nine studies (427 participants) met the inclusion criteria for this review. Four of these (192 participants) assessed the effectiveness
of donepezil, two (139 participants) assessed memantine, one (21 participants) assessed simvastatin, one study (35 participants) assessed
antioxidants, and one study (40 participants) assessed acetyl-L-carnitine.
Five studies focused on adults aged 45 to 55 years, while the remaining four studies focused on adults aged 20 to 29 years. Seven studies
were conducted in either the USA or UK, one between Norway and the UK, and one in Japan. Follow-up periods in studies ranged
from four weeks to two years. The reviewers judged all included studies to be at low or unclear risk of bias.
Analyses indicate that for participants who received donepezil, scores in measures of cognitive functioning (standardised mean difference
(SMD) 0.52, 95% confidence interval (CI) -0.27 to 1.13) and measures of behaviour (SMD 0.42, 95% CI -0.06 to 0.89) were similar
to those who received placebo. However, participants who received donepezil were significantly more likely to experience an adverse
event (odds ratio (OR) 0.32, 95% CI 0.16 to 0.62). The quality of this body of evidence was low. None of the included donepezil
studies reported data for carer stress, institutional/home care, or death.
For participants who received memantine, scores in measures of cognitive functioning (SMD 0.05, 95% CI -0.43 to 0.52), behaviour
(SMD -0.17, 95% CI -0.46 to 0.11), and occurrence of adverse events (OR 0.45, 95% CI 0.18 to 1.17) were similar to those who
received placebo. The quality of this body of evidence was low. None of the included memantine studies reported data for carer stress,
institutional/home care, or death.
Due to insufficient data, it was possible to provide a narrative account only of the outcomes for simvastatin, antioxidants, and acetyl-
L-carnitine. Results from one pilot study suggest that participants who received simvastatin may have shown a slight improvement in
cognitive measures.
Authors’ conclusions
Due to the low quality of the body of evidence in this review, it is difficult to draw conclusions about the effectiveness of any
pharmacological intervention for cognitive decline in people with Down syndrome.
P L A I N L A N G U A G E S U M M A R Y
Medications for cognitive decline in people with Down syndrome
People with Down syndrome often experience cognitive decline (a deterioration in memory, language, thinking and judgment that are
greater than normal age-related changes) at a younger age and in greater numbers than the general population. Various medicines have
been shown to improve, or at least slow down the progression of these symptoms in people without Down syndrome.
Review question
Do adults (18 years and older) with Down syndrome benefit from treatment with medicine to prevent cognitive decline, compared
with other adults with Down syndrome who receive either fake medicine (placebos) or no medicine?
Study characteristics
In January 2015, we, a team of Cochrane researchers, searched for all medical studies that investigated the effect of any medicine or
nutritional supplement on cognitive decline in adults with Down syndrome. We found nine relevant randomised controlled trials (this
design produces the most reliable results) that we could include in this overview. These studies tested:
- donepezil, a medicine used to treat Alzheimer’s disease (four studies);
- memantine, a medicine used to treat Alzheimer’s disease (two studies);
- simvastatin, a (statin) medicine used to prevent heart disease (one study);
- a mixture of antioxidants, including forms of vitamins C and E, and alpha-lipoic acid (one study); and
- acetyl-L-carnitine, a dietary supplement that has previously been used to treat dementia (one study).
Five of the studies focused on adults aged 45 to 55 years and four focused on adults aged 20 to 29 years. Seven studies were conducted
in either the USA or UK, one took place in Norway and the UK, and one study was conducted in Japan.
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Key results
The nine studies we found examined the effects of five medicines that are, or have been, used to prevent cognitive decline. All the
studies compared the medicine being tested with a placebo (a tablet or capsule that looked and tasted like the medicine, but which
contained no medicine).
Generally, those who received the medicine did no better than those who received the placebo in any of the areas assessed in the studies.
The areas assessed included general functioning (including memory and thinking, speech, mood and behaviour); cognitive functioning
(including memory, following what’s going on around you); adaptive behaviours (being able to do day-to-day tasks); or behaviour
problems (such as being irritable or aggressive).
The only medicine to show any positive effect was the statin, simvastatin. Preliminary findings from a very small study showed that
simvastin had some benefit on improving memory compared to placebo.
In the four donepezil studies, those participants given donepezil reported more headaches, dizziness, and nausea than participants
given placebo. In the two memantine studies, there was no difference between participants given memantine or placebo for reports of
headaches, dizziness, and nausea.
Quality of the evidence
Although the included studies were well conducted, most involved small numbers of participants and for many of the areas assessed we
could not combine results from two or more studies. Overall, the quality of this evidence is low. We cannot be certain whether any of
these medicines are effective. Running more trials with more people over a longer period of time would allow us answer this question
with greater certainty.
We could not find any trials that investigated many of the medicines used to prevent cognitive decline, and so research is needed to
explore the effectiveness of these medications in the Down syndrome population.
3Pharmacological interventions for cognitive decline in people with Down syndrome (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Comparison 1: donepezil versus placebo
Patient or population: people with Down syndrome
Setting: clinic
Intervention: donepezil
Comparison: placebo
Outcomes Absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Cognit ive abilit ies (Se-
vere Impairment Bat-
tery; SIB)
Follow-up: 12 to 24
weeks
- The mean change in
cognit ive abilit ies in
the intervent ion groups
was 0.52 points higher
(0.27 lower to 1.31
higher)
- 165
(3 RCTs)
⊕⊕©©
Low¹
-
Behavioural problems
(various scales)
Follow-up: 12 to 24
weeks
- The mean change in
behavioural problems
the intervent ion groups
was 0.42 points higher
(0.06 lower to 0.89
higher)
- 157
(3 RCTs)
⊕⊕©©
Low²
-
Risk with placebo Risk with donepezil - - - -
Adverse events
Follow-up: 12 to 24
weeks
Study populat ion OR 0.32
(0.16 to 0.62 )
192
(4 RCTs)
⊕⊕©©
Low³
-
351 per 1000 630 per 1000
(467 to 768)
Moderate
157 per 1000 370 per 1000
(232 to 533)
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Carer stress No data available No data available - - - -
Inst itut ional/ home care No data available No data available - - - -
Death No data available No data available - - - -
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; GRADE: Grades of Recommendations, Assessment, Development and Evaluat ion; RR: risk rat io; OR: odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded two levels for imprecision (wide conf idence interval) and inconsistency (I² = 74%).
2 Downgraded two levels for imprecision (wide conf idence interval) and inconsistency (I² = 36%).
3 Downgraded two levels for serious imprecision (wide conf idence interval) and small number of events.
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B A C K G R O U N D
Description of the condition
Down syndrome is the most common genetic disorder recognised
at birth and is caused by an extra copy of chromosome 21, or the
translocation of part of chromosome 21, onto another chromo-
some (Loane 2014; Papalia 2001).
As the care and environment of people with Down syndrome has
improved, so their life expectancy has improved (Bittles 2010;
Yang 2002). Life expectancy is currently 58 years (Wu 2013), with
25% living beyond 63 years (Glasson 2002). Survival of babies
with Down syndrome increased significantly in the 1950s, and
there is currently a population bulge of those aged 40 to 55 (Wu
2013).
The extra copy of the amyloid precursor protein (APP) gene,which
is located on chromosome 21, causes the early onset of Alzheimer’s
disease pathology: cerebral amyloid plaques are present in almost
all cases, developing some 50 years earlier than in normal aging
(Mann 1989; Rumble 1989). Consequently, people with Down
syndrome are vulnerable to developing dementia at an earlier age:
prevalence runs at 10% between the ages of 40 and 49 years, 40%
between the ages of 50 and 59 years (Holland 1998), and 56% in
those over 60 (Janicki 2000). This is greater than the rate seen in
other causes of neurodevelopmental delay, which runs at 2% to
3% at 40 years of age (Janicki 2000).
However, as in the general population, significant numbers of older
people with Down syndrome and cerebral amyloid plaques do
not develop dementia. Indeed, cerebral amyloid plaques may be
unrelated to cognitive impairment in people withDown syndrome
who do not have dementia (Hartley 2014), and neurofibrillary
tangles develop considerably later than the amyloid deposition (
Hof 1995). Additional factors such as vascular pathology, cognitive
reserve (Mullins 2013; Temple 2001), or additional genetic risks
such as Apolipoprotein E (ApoE4; Jones 2013; Rohn 2014), may
influence the development of cognitive decline and dementia.
Although progression from Alzheimer’s disease to Alzheimer’s de-
mentia affects people with Down syndrome in similar ways to
thosewithoutDown syndrome, there are somenotable differences.
Firstly, the rate of decline may be more rapid in people with Down
syndrome. Secondly, diagnosis may be delayed because existing
cognitive deficits may make changes in behaviour, confusion, and
living skills more difficult to detect (Watchman 2013). Thirdly,
behavioural changes of apathy and disinhibition are particularly
common in pre-dementia decline in Down syndrome, and are
suggestive of prominent frontal lobe impairment (Ball 2008).
Dementia and cognitive decline can cause significant distress and
add to the burden of caring for people with Down syndrome.
Changes in adaptive behaviour are common and 24-hour surveil-
lance over a period of years is required, which places caregivers at a
high risk of adverse health consequences (Bittles 2004; CSHAWG
2002).
Consideration of the performance of differing diagnostic criteria
of dementia in Down syndrome is beyond the scope of this review
and is reviewed elsewhere (Sheehan 2015).
Description of the intervention
There is noknowncure for dementia, but psychological treatments
have been found to be effective in helping people to cope with the
symptoms (Forbes 2013; Woods 2012).
In addition, drugs from two classes are licensed for the treatment
of Alzheimer’s disease: the cholinesterase inhibitors (donepezil,
galantamine and rivastigmine), and the N-methyl-D-aspartate
(NMDA) receptor antagonist, memantine. Trials of other inter-
ventions, such as vitamin E, B vitamins and statins have provided
conflicting evidence of benefit.
It is also not known whether there are interventions that might
affect progression of cognitive decline in participants without a
formal diagnosis of dementia.
How the intervention might work
A number of pharmacological interventions are currently available
and operate through a range of mechanisms.
Donepezil, galantamine and rivastigmine work by inhibiting the
enzyme acetylcholinesterase, thereby increasing the level of the
neurotransmitter acetylcholine between nerve cells in the brain.
They provide a modest symptomatic boost, improving cognitive
and functional ability in those with mild to severe dementia. Over
two years, this may be sufficient to reduce mortality, at least for
galantamine (Hager 2014). The risks are considered to outweigh
the benefits inmild cognitive impairment (Tricco 2013). Themain
side effects are loss of appetite, nausea, diarrhoea, headache, in-
somnia and slowed heart rate.
Memantine is an antagonist of the NMDA glutamate receptor. It
has a small benefit, including in those already taking cholinesterase
inhibitors. The benefit is confined to those withmoderate or severe
Alzheimer’s disease and is consistent with the proposedmechanism
of action: reduction of excitotoxicity and subsequent damage and
death of neurons. It is a well tolerated drug (Gauthier 2013).
High dose vitamin E, an antioxidant, has been reported as show-
ing benefit in trials of severe (Sano 1997), and mild-to-moderate
Alzheimer’s disease (Dysken 2014). The lack of effect on cogni-
tion, theoretical concerns about safety, and lack of industrial back-
ing for marketing have, thus far, militated against widespread use
(Corbett 2014).
A single study has indicated that high dose vitamin B12 and folate
may reduce progression of brain atrophy in mild cognitive impair-
ment, with cognitive benefit in those with high levels of the amino
acid homocysteine (Douaud 2013).
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
(DYRK1A) may be important in the pathophysiology of intellec-
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tual deficit in Down syndrome. Research has indicated that epigal-
locatechin-3-gallate reduces DYRK1A activity in the hippocam-
pus (De la Torre 2014).
The incidence of dementia in the general population is reduc-
ing slightly. This raises the possibility that strategies that improve
vascular health (Matthews 2013), such as statins and antihyper-
tensives, may also reduce dementia, although this has not been
securely established in randomised trials (Ligthart 2010; Power
2015). It remains unknown whether this applies to a Down syn-
drome population.
It is not known whether the benefits and risks seen in the general
population would differ in those with Down syndrome.
Why it is important to do this review
In 2009, four Cochrane Reviews were published of the licensed
treatments for Alzheimer’s disease in people with Down syndrome
(Mohan 2009a;Mohan 2009b;Mohan 2009c;Mohan 2009d). At
that time, only one review identified a trial that met its inclusion
criteria, namely a small randomised trial of donepezil. The reviews
concluded that nothing was then known about the effectiveness
of licensed treatments for Alzheimer’s disease in this population.
This review aimed to achieve three things:
1. to update the evidence base;
2. to bring together, in one place, the available evidence of
both licensed treatments and other available treatments for this
population; and
3. to examine the impact of these pharmacological
interventions on cognitive impairment, which does not meet the
criteria for dementia.
An up-to-date review of this kind is important, not least because
people with learning disabilities (including Down syndrome) are
often on a large amount of medication, despite limited evidence of
its effectiveness and evidence of considerable harmful side effects
(RCGP 2012).
O B J E C T I V E S
To assess the effectiveness of anti-dementia pharmacological in-
terventions and nutritional supplements for treating cognitive de-
cline in people with Down syndrome.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing one relevant anti-
dementia pharmacological intervention or nutritional supplement
with another, or with placebo or no treatment.
Types of participants
Adults (aged 18 years and older) with Down syndrome.Where we
identified relevant studies that included participants younger than
18 years of age or participants that did not have Down syndrome,
we contacted the study authors to request the subgroup data for
participants with Down syndrome, aged 18 years and older only.
If the authors were unable or unwilling to provide this data, the
study was excluded from the review. Information from one such
study is presented (Eisenburg 1984).
Types of interventions
Any anti-dementia pharmacological intervention or nutritional
supplement that has a putative effect on cognitive function. Rel-
evant interventions include, but are not limited to: donepezil,
galantamine, memantine, rivastigmine, piracetem, acetyl-Lcarni-
tine, antioxidant supplementation, vitamin supplementation, and
DYRK1A inhibitors (green tea extract).
Types of outcome measures
Primary outcomes
1. Improvement in:
i) cognitive abilities, as measured by standardised scales,
for example, the Dementia Scale for Down Syndrome (DSDS;
Jozsvai 2009), the Cambridge Cognitive Examination
(CAMCOG; Schmand 2000), or the Severe Impairment Battery
(SIB; Panisset 1994; Saxon 1993);*
ii) global functioning, as measured by standardised scales,
for example, the DSDS (Jozsvai 2009), or the International
Classification of Functioning, Disability and Health (ICF) Scales
(WHO 2001);
iii) behavioural problems, as measured by standardised
scales, for example, the American Association on Mental
Deficiency: Adaptive Behaviour Scale (AAMD: ABS; Nihira
1974), or the Neuropsychiatric Inventory (NPI; Cummings
1994);*
iv) daily living skills, including kitchen skills, laundry
skills, self-care skills, etc. (as measured by carer report).
2. Adverse events, including headache, nausea, and dizziness.*
Secondary outcomes
1. Carer stress (as measured by interviews or self reports).*
2. Institutional/home care, including social care placement
breakdown (as measured by administrative data).*
3. Death (as measured by administrative data).*
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4. Treatment adherence (as measured by administrative data
and self report).
Had data been sufficient, we intended to make comparisons at the
following specific follow-up periods:
1. short term (less than three months);
2. medium term (three to 12 months); and
3. long term (over one year).
Outcomes indicated by an asterisk (*) above are presented in two
’Summary of findings’ tables (Summary of findings for the main
comparison; Summary of findings 2).
Search methods for identification of studies
Electronic searches
The following databases were searched in January 2015.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; part of the Cochrane Library; 2014, Issue 12;
includes the Specialised Register of the Cochrane
Developmental, Psychosocial and Learning Problems Group).
2. ALOIS (Specialised Register of the Cochrane Dementia and
Cognitive Improvement Group, up-to-date as of 1 January
2015).
3. Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations (1946 to January Week 2 2015).
4. Embase (Ovid; 1974 to 2015 Week 3).
5. PsycINFO (Ovid; 1806 to January Week 2 2015).
6. CINAHL (EBSCOhost; 1937 to 20 January 2015).
7. Science Citation Index (Web of Science; 1970 to 20
January 2015).
8. Social Sciences Citation Index (Web of Science; 1970 to 20
January 2015).
9. Conference Proceedings Citation Index - Science (Web of
Science; 1970 to 20 January 2015).
10. Conference Proceedings Citation Index - Social Science &
Humanities (Web of Science; 1970 to 20 January 2015).
11. Cochrane Database of Systematic Reviews (CDSR; part of
the Cochrane Library; 2015, Issue 1).
12. Database of Abstracts of Reviews of Effects (DARE; part of
the Cochrane Library; 2014, Issue 4).
13. ClinicalTrials.gov (clinicaltrials.gov; 20 January 2015).
14. World Health Organisation (WHO) International Clinical
Trials Registry Platform (ICTRP; apps.who.int/trialsearch; 20
January 2015).
The Trials Search Co-ordinator of the Cochrane Developmental,
Psychosocial and Learning Problems Group searched 13 of the 14
databases. The final database (ALOIS) was searched by the Trials
Search Co-ordinator of the Cochrane Dementia and Cognitive
Improvement Group.
The exact search strategy and date of search for each database can
be found in Appendix 1. We did not apply any language or date
restrictions.
Searching other resources
We contacted relevant authors, key scholars, Down syndrome vol-
untary organisations and themanufacturers of all relevant drugs to
ask about reports of unpublished or ongoing trials (see Appendix
2).
We scanned the bibliographies of relevant reviews, and of included
and excluded studies for additional references of interest.
Data collection and analysis
Selection of studies
Two review authors (NL and JH) independently reviewed the ti-
tles and abstracts of all records located during the search process
and assessed each study to determine whether it met the inclusion
criteria for this review. Full text articles were retrieved for records
that appeared to meet the inclusion criteria. Two review authors
(NL and JH) then independently assessed these records. Any dis-
agreements between the authors were discussed with the full re-
view team until they were resolved.
Data extraction and management
Two review authors (NL and JH) independently extracted and en-
tered data into a piloted data extraction form. Any disagreements
between the authors were discussed with the full review team until
they were resolved.
We extracted the following data:
1. study characteristics (including study design, setting,
recruitment procedures, details of attrition);
2. intervention characteristics (including type of drug,
duration, dosage, frequency, age medication began, and
concurrent interventions);
3. participants’ characteristics (including number randomised,
age distribution, gender, method of diagnosis, inclusion or
exclusion criteria, number (total per group));
4. comparison characteristics (including duration, dosage,
frequency); and
5. outcome data (including relevant details on all primary and
secondary outcome measures used, loss to follow-up, length of
follow-up, and summary data, including means, standard
deviations (SDs), confidence intervals (CIs), and significance
levels for continuous data and proportions for dichotomous
data).
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Assessment of risk of bias in included studies
Two review authors (NL and JH) assessed each included study for
risk of bias, using the Cochrane ’Risk of bias’ tool (Higgins 2011).
Review authors judged each of the seven domains (below) assessed
by the tool to be at either ’low risk of bias’, ’high risk of bias’, or
’unclear risk of bias’:
1. sequence generation (was the method used to generate the
allocation sequence adequate?);
2. allocation concealment (was the method of concealing the
allocation sequence sufficient, both prior to, and during the
recruitment process?);
3. blinding of participants and personnel (was knowledge of
the allocated intervention adequately concealed from all
participants and relevant personnel during the study?);
4. blinding of outcome assessors (was knowledge of the
allocated intervention adequately concealed from all outcome
assessors during the study?);
5. incomplete outcome data (did study authors address issues
related to incomplete outcome data adequately?);
6. selective outcome reporting (are reports of the study free of
suggestion of selective outcome reporting?); and
7. other sources of bias (was the study apparently free of other
problems that could put it at a high risk of bias, for example,
source of study funding?).
Measures of treatment effect
Dichotomous data
For dichotomous outcome data (e.g. institutionalisation or death),
we calculated effect sizes as odds ratio (OR) with 95% CIs. For
studies with no events in a treatment arm, a fixed value of 0.5 was
added to each ’zero event’ cell of the contingency table to allow
the calculation of an OR.
When an eligible study did not report data used to calculate sum-
mary measures, we made efforts to transform the data provided
into the appropriate data. When necessary, we contacted study
authors to request the required information.
Continuous data
When study authors used different measures to assess the same
outcome, we converted continuous outcome data (e.g. cognitive
abilities or behavioural problems) into standardised mean differ-
ences (SMDs) and presented these with 95% CIs. More informa-
tion on the protocol methods to be used in future updates of this
review are detailed in Appendix 3 (Livingstone 2015).
Time-to-event data
No relevant time-to-event data were included in this review. In
the event that future updated searches are able to locate reports of
additional studies that meet the inclusion criteria for this review,
any time-to-event data identified will be analysed using the meth-
ods detailed in Appendix 3.
Multiple outcomes
It was not necessary to combine multiple interchangeable contin-
uous or dichotomous measures of the same construct at the same
point in time in this review. In the event that this becomes nec-
essary in future updates of this review, we will use the methods
detailed in Appendix 3.
Economic issues
None of the included studies provided data on the cost of pro-
grammes within the studies under review. In the event that future
updated searches are able to locate reports of eligible additional
studies that address economic issues, they will be analysed using
the methods detailed in Appendix 3.
Unit of analysis issues
No cluster randomised trials or studies with multiple treatment
groups were identified in this review. One cross-over trial could
not be included as the participants’ ages ranged above and below
18 years, and individual participant data were not available from
the authors (Eisenburg 1984). If unit of analysis issues arise in
future updates of this review, they will be dealt with using the
methods detailed in Appendix 3.
Dealing with missing data
We contacted authors and asked them to supply data missing from
included studies where necessary.
It was not necessary to impute any missing participant data in this
version of the review. if imputation of missing data is required
in a future update, it will be done using the methods detailed in
Appendix 3.
In the event of missing summary data, such as missing SDs, we
obtained these using calculations provided in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
We examined clinical heterogeneity by inspecting variability in
the participants, interventions and outcomes described in each
included study within each comparison made. We examined
methodological heterogeneity by inspecting variability in the study
design and risk of bias of each included study within each com-
parison made. We assessed statistical heterogeneity using the Q
statistic and its P value (less than 0.10 suggesting statistical sig-
nificance), the I² statistic along with the 95% CI for heterogene-
ity variance, and by visual inspection of the forest plots. Due to
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the potential unreliability of the I² statistic, we also presented the
magnitude of the heterogeneity.
Where possible, we pooled data from studies that were sufficiently
similar to minimise heterogeneity.
Assessment of reporting biases
There were insufficient studies (< 10) of any intervention to allow
us to assess publication bias and other reporting biases using funnel
plots. In the event that future updated searches are able to locate
reports of additional studies that meet the inclusion criteria for
this review, they will be analysed using the methods detailed in
Appendix 3.
Data synthesis
We performed a meta-analysis on outcome data where we found
at least two studies suitable for inclusion that studied the
same intervention. We accounted for the expected heterogeneity
among included studies by using a random-effects meta-analysis
(DerSimonian 1986) in RevMan (Review Manager 2014). The
random-effectsmodel was used to incorporate the assumption that
the different studies estimate different, yet related, intervention
effects (Higgins 2011).
We converted continuous outcome data (i.e. cognitive abilities and
behavioural problems) into SMDs and presented these with 95%
CIs using the inverse varianceweightingmethod. For dichotomous
outcome data (i.e. adverse events), we calculated effect sizes asORs
with 95% CIs. We used the Mantel-Haenszel method for analysis
of dichotomous outcomes, as It has been shown that this method
has better statistical properties when few events are available.
When ameta-analysis was not possible due to an insufficient num-
ber of studies, we provided a narrative description of the study
results.
For the purpose of this review, we extracted and synthesised sum-
mary data (i.e. means and SDs) primarily from journal publica-
tions. Individual patient data (IPD) were not available for any of
the included studies in this review. In the event that future searches
locate reports of additional studies that meet the inclusion criteria
for this review, and such data are available, we will incorporate
IPD using the methods detailed in Appendix 3.
Summary of Findings Table
For the identified outcomes (see above), we created ’Summary of
findings’ tables for the twomain comparisons using the system and
software developed by the Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) Working Group
(GRADEpro GDT 2014; Review Manager 2014). For informa-
tion regarding the GRADE approach and factors that influence
the assessment, see Table 1, Table 2, and Table 3.
Subgroup analysis and investigation of heterogeneity
There were insufficient studies to allow for meaningful subgroup
analyses. In the event that future searches locate reports of addi-
tional studies that meet the inclusion criteria for this review, and
provide enough data for subgroup analyses, we will analyse the
studies using the methods detailed in Appendix 3.
Sensitivity analysis
Similarly, there were insufficient studies to support meaningful
sensitivity analyses in this review (see Appendix 3 for details of
designated methods for sensitivity analyses).
R E S U L T S
Description of studies
Results of the search
A systematic search, conducted in January 2015, identified 1220
unique records of potentially relevant trials. Of these, 1126 records
were deemed irrelevant following inspection of their titles and
abstracts. The full texts were obtained and read for the remaining
94 records. Following this, a further 65 irrelevant reports were
excluded. We formally excluded another 11 reports (documented
in Excluded studies).
Ten studies (with 16 reports) met our inclusion criteria for studies
of pharmacological interventions for cognitive decline in people
with Down syndrome.
Two additional reports were categorised as ongoing studies (Aisen
2005; NCT01791725; See Characteristics of ongoing studies).
See Figure 1 for the study flow diagram.
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Figure 1. Study flow diagram
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Included studies
In this review, we report on nine of the 10 studies that met the
inclusion criteria for this review, six of which contribute data to
meta-analyses. Four of these six studies assessed the effectiveness of
donepezil (Johnson 2003; Kishnani 2009; Kondoh 2011; Prasher
2002), while the other two studies assessed the effectiveness of
memantine (Boada 2012; Hanney 2012). The remaining three
studies assessed the effectiveness of simvastatin (Cooper 2012),
antioxidants (Lott 2011), and acetyl-L-carnitine (Pueschel 2006).
The tenth study included participants aged 10 to 42 years
(Eisenburg 1984). We contacted the authors of this study to re-
quest data for participants aged 18 to 42 years only. The author
replied that it would not be possible to access any information
beyond what was available in the published paper. Therefore, we
adhered to the plan outlined in our original protocol (Livingstone
2015), and have not included this study in the results section of
this review. We have included more details of this study in an ad-
ditional table (Table 4).
See Characteristics of included studies for further information.
Location in which studies conducted
Five studies were conducted in the USA (Boada 2012; Johnson
2003; Kishnani 2009; Lott 2011; Pueschel 2006); two in the UK
(Cooper 2012; Prasher 2002), and the remaining two studies in
Norway and the UK (Hanney 2012), and Japan (Kondoh 2011).
Study design
All nine included studies were RCTs.
Participants
Participants in all included studies had a genetically karyotyped
diagnosis of Down syndrome. In two of the studies (Hanney
2012; Prasher 2002), participants also had a diagnosis of mild-
to-moderate Alzheimer’s disease, according to the International
Classification ofDiseases, 10th Revision (ICD-10) criteria (WHO
1992).
Four of the studies focused primarily on young adults with Down
syndrome (Boada 2012; Johnson 2003; Kishnani 2009; Pueschel
2006); the mean age of participants in these studies ranged from
20.2 years to 29.5 years. The remaining five studies focused on
middle-aged adults with Down syndrome (Cooper 2012; Hanney
2012; Kondoh 2011; Lott 2011; Prasher 2002); the mean age of
participants in these studies ranged from 45.6 years to 55.07 years.
The gender distribution of participants was relatively even (40% to
60% male) in five studies (Cooper 2012; Hanney 2012; Johnson
2003; Lott 2011; Prasher 2002). One study focused predomi-
nantly on males (62% male; Kishnani 2009), and another pre-
dominantly on females (37% males; Boada 2012). One study fo-
cused exclusively on males (Pueschel 2006), and one exclusively
on females (Kondoh 2011).
Interventions
Participants in three of the four donepezil studies received 5 mg of
donepezil per day for the first four to six weeks of the study, and
10 mg per day thereafter (Johnson 2003; Kishnani 2009; Prasher
2002). Participants in the remaining donepezil study received 3
mg/day for 24 weeks (Kondoh 2011).
Participants in the Boada 2012 study received 5 mg memantine
once daily in week one, 5 mg twice daily (10 mg) in week two, 5
mg per day and 10 mg per day (15 mg; one divided dose) in week
three, and 10 mg twice daily (20 mg) from week four to week 16.
Participants in the Hanney 2012 memantine study received 5 mg
per day for eight weeks, which then increased to 10 mg per day
with fixed titration.
Participants in the antioxidant study received 900 IU of alpha-
tocopherol with 200 mg of ascorbic acid and 600 mg of alpha-
lipoic acid per day for 24 months (Lott 2011).
Participants in the Cooper 2012 study received 40 mg simvastatin
once per day.
Participants in the Pueschel 2006 study received 10 mg/kg acetyl-
L-carnitine per day during the first month, followed by 20 mg/kg
per day in second month and 30 mg/kg per day for the rest of the
study.
All studies used placebo tablets that were identical to the interven-
tion tablet.
Duration of follow-up
The follow-up periods of the included studies ranged from four
weeks to two years. The donepezil trials included follow-up at four
weeks (Johnson 2003), after 12 weeks (Johnson 2003; Kishnani
2009), and after 24 weeks (Kondoh 2011; Prasher 2002). The
two memantine trials had follow-up periods of 16 weeks (Boada
2012), and 52 weeks (Hanney 2012). The simvastatin study fol-
lowed participants for up to 52 weeks (Cooper 2012). The an-
tioxidant study included both one year (52-week) and two year
(104-week) follow-ups (Lott 2011). Finally, the trial of acetyl-L-
carnitine followed up with participants after three and six months
of treatment, and again following a three-month washout period
(nine months after commencing treatment (Pueschel 2006).
Outcomes
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Primary outcomes
Cognitive abilities
Cognitive functionwas assessed in eight out of nine of the included
studies using a range of different scales. Four studies, Johnson
2003, Kishnani 2009, Lott 2011 and Prasher 2002, assessed cog-
nition using the Severe Impairment Battery (SIB; Panisset 1994;
Saxon 1993).
Lott 2011 also assessed cognitive function using the Dementia
Questionnaire for Mentally Retarded Persons (DMR; Evenhuis
1996) and the Brief Praxis Test (BPT; Dalton 1997).
Hanney 2012 assessed cognition using the Down syndrome
Attention, Memory and Executive Functions Scales (DAMES;
Margallo-Lana 2003), and Boada 2012 used the Differential Abil-
ity Scales-II Matrices (DAS-II; Elliott 2007; Elliott 2010).
Pueschel 1980 used the Stanford-Binet Intelligence Scale (Fourth
Edition;Thorndike 1986), andCooper 2012 used theMemory for
Objects Test from the NADIID (Neuropsychological Assessment
of Dementia in Intellectual Disabilities Battery; Oliver 1998).
Global functioning
Two studies reported on global functioning: Kondoh 2011 as-
sessed this outcome using the International Classification of Func-
tioning, Disability and Health (ICF) Scales (WHO 2001), while
Lott 2011 assessed this outcome using the Sum of Social Scores
on the DMR (DMR SOS; Evenhuis 1996).
Behavioural problems
Behaviour was assessed in seven of the nine included studies, us-
ing a range of scales. Boada 2012 and Johnson 2003 assessed
behaviour using the Scales of Independent Behavior - Revised
(SIB-R; Bruininks 1996). Kishnani 2009 and Lott 2011 used the
Vineland Adaptive Behavior Scales (VABS; Sparrow 2006), and
Hanney 2012 and Prasher 2002 used the American Association on
Mental Deficiency: Adaptive Behavior Scale (AAMDABS; Nihira
1974). Pueschel 2006 assessed behaviour using theChild Behavior
Checklist (CBCL; Achenbach 1983).
Daily living skills
Three studies assessed daily living skills: Cooper 2012 reported
this outcome using the American Association of Mental Retar-
dation: Adaptive Behavior Scale (AAMR: ABS) - Residential and
Community (Nihira 1993); Lott 2011 used the Bristol Activities
of Daily Living Scale (BADLS; Bucks 1996); and Pueschel 2006
used the Daily Living Skills subtest of the VABS (Sparrow 2006).
Adverse events
All nine included studies reported data on adverse events.
Secondary outcomes
Carer stress
Cooper 2012measured carer stress using theGeneralHealthQues-
tionnaire-12 (GHQ-12; Goldberg 1988).
Institutional/home care
Pueschel 2006 summarised results of an analysis on living arrange-
ments, but provided no numerical data for this outcome.
Death
None of the included studies assessed postintervention death rates.
Treatment adherence
Two of the included studies provided information on adherence
to treatment (Cooper 2012; Lott 2011).
Methodological heterogeneity
There was no unexpected variability in the methodological het-
erogeneity in each included study. All included studies made use
of a RCT design, and most had similar levels of low or unclear risk
of bias.
Clinical heterogeneity
There was some clinical heterogeneity amongst the included stud-
ies. Whilst most of the participants across all studies were of a
similar age (mean ages ranged from 45 to 55 years), four of the
nine studies focused on younger adults (20 to 29 years).
The administration of all interventions followed a similar format.
Similar outcomes were measured by all studies. We identified a
total of five different interventions in this review and judged these
to be too heterogenous to combine. We decided to compare each
type of intervention separately, which led to a total of five com-
parisons in this review.
1. Comparison 1: donepezil versus placebo.
2. Comparison 2: memantine versus placebo.
3. Comparison 3: simvastatin versus placebo.
4. Comparison 4: antioxidants versus placebo.
5. Comparison 5: acetyl-L-carnitine versus placebo.
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Statistical heterogeneity
Since we found only one study for comparisons three, four and
five, meta-analyses were only possible for the first two of the five
comparisons listed above. For these two comparisons, statistical
heterogeneity (as measured by the I²) ranged from 0% to 74% for
the comparison of donepezil versus placebo, and 0% to 41% for
the comparison of memantine versus placebo.
Excluded studies
We excluded 11 studies from this review: four because they were
not RCTs (Boada-Rovira 2005; Gedye 1991; Schill 2005; Thase
1982); two because, although they were randomised trials, the
participants were children under 18 years of age (Lobaugh 2001;
Pueschel 1980); three because they only provided an overview of
the current state of evidence, and did not provide an evaluation
or any new data (Barr 1990; Breeze 2012; Shinagawa 2014); and
two because they focused on comparing the effect of their inter-
vention in participants with Down syndrome to those without
Down syndrome (Arvat 1996; De Falco 1994). SeeCharacteristics
of excluded studies tables for further information.
Risk of bias in included studies
See: ’Risk of bias’ tables (beneath the Characteristics of included
studies tables), Figure 2, and Figure 3 for further information.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
14Pharmacological interventions for cognitive decline in people with Down syndrome (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
We judged the method of generating a random sequence to be ad-
equate in seven of the nine included studies, resulting in a judge-
ment of low risk of selection bias for those studies (Boada 2012;
Cooper 2012; Hanney 2012; Johnson 2003; Lott 2011; Prasher
2002; Pueschel 2006). We judged the remaining two studies as
being at unclear risk of bias due to insufficient reporting (Kishnani
2009; Kondoh 2011). We contacted the authors of both papers
for more information, but none had replied at the time of publi-
cation.
We also judged the method of concealing the random allocation
method to be adequate in seven of the nine included studies, re-
sulting in a judgement of low risk of selection bias for those stud-
ies (Boada 2012; Cooper 2012; Hanney 2012; Johnson 2003;
Kondoh 2011; Lott 2011; Pueschel 2006).We judged the remain-
ing two studies as being at unclear risk of bias due to insufficient re-
porting (Kishnani 2009; Prasher 2002).We contacted the authors
of both papers for more information. The authors of Kishnani
2009 have not yet replied, but the authors of Prasher 2002 sent
their apologies and stated it would not be possible to obtain the
necessary information.
Blinding
Blinding of participants, personnel, and outcome assessors was
judged to be adequate in eight of the nine included studies, result-
ing in a judgement of low risk of performance bias and detection
bias for those studies (Boada 2012; Cooper 2012; Hanney 2012;
Johnson 2003; Kondoh 2011; Lott 2011; Prasher 2002; Pueschel
2006). The remaining study was judged as being at unclear risk of
bias due to insufficient reporting (Kishnani 2009). We contacted
the authors of this paper for more information, but they have not
yet replied.
Incomplete outcome data
The reported analyses of five of the nine included studies ac-
counted for all participants appropriately, resulting in a judgement
of low risk of attrition bias for those studies (Boada 2012; Hanney
2012; Johnson 2003; Kondoh 2011; Lott 2011). In Prasher 2002,
it was unclear whether the analyses were based on the 30 partic-
ipants randomised or the 27 available at follow-up. In response
to a request for further information, the authors informed us that
it would not be possible to obtain the necessary information. In
Pueschel 2006, it was also unclear how many of the original 40
participants randomised were included in the final analysis. The
remaining two studies were judged to be at low risk of attrition
bias for attrition bias (Cooper 2012; Kishnani 2009): although
a small number of participants in these studies were lost to fol-
low-up and not included in the final analyses, the dropouts were
balanced across the arms of the studies, so it is unlikely that this
introduced bias.
Selective reporting
We judged outcome reporting to be sufficient in four studies, as all
outcomes planned in the protocol were reported; this resulted in
judgements of low risk of reporting bias for these studies (Boada
2012; Cooper 2012; Johnson 2003; Lott 2011). We were unable
to locate the protocols of three studies, either through searching or
through contacting the authors (Kishnani 2009; Kondoh 2011;
Prasher 2002). Therefore, we judged these studies to be at an un-
clear risk of reporting bias. The overall reporting of the results for
the remaining two studies was poor and there were discrepancies
between what was measured according to the methodology and
what was presented in the results (Hanney 2012; Pueschel 2006).
Specifically, the trial authors did not report on outcomes that they
had listed as outcome measures, and did report on outcomes they
had not mentioned in the methods section. We judged these stud-
ies to be at a high risk of reporting bias.
Other potential sources of bias
Two studieswere fundedby the drugmanufacturer (Johnson 2003;
Kishnani 2009). As these reports did not state whether the funder
was involved in any aspect of the study, we judged them to be at
unclear risk of other bias.We judged the remaining seven studies to
be at a low risk of other bias (Boada 2012; Cooper 2012; Hanney
2012; Kondoh 2011; Lott 2011; Prasher 2002; Pueschel 2006).
Effects of interventions
See:Summaryof findings for themain comparisonComparison
1: donepezil versus placebo; Summary of findings 2Comparison
2: memantine versus placebo
Comparison 1: donepezil versus placebo
See Summary of findings for the main comparison.
Primary outcomes
Cognitive abilities
Three studies (165 participants) looked at the impact of donepezil
on cognitive function in people with Down syndrome using
the SIB (Johnson 2003; Kishnani 2009; Prasher 2002). When
combined in a meta-analysis, there was no difference between
donepezil and control groups at 12 to 24 weeks postintervention
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(SMD 0.52, 95% CI -0.27 to 1.13; I² = 74%; P value for hetero-
geneity 0.02; τ ² = 0.35; Analysis 1.1; Figure 4). Using theGRADE
approach, this outcome was downgraded from high to low quality
evidence due to imprecision of the effect and inconsistency of the
result.
Figure 4. Forest plot of comparison: 1 Comparison 1: Donepezil versus placebo, outcome: 1.1 Cognitive
abilities (Severe Impairment Battery) 12 to 24 weeks
Global functioning
Only one study (42 participants) reported the impact of donepezil
on global functioning in people with Down syndrome using the
abridged edition of the ICF scales and subscales (Kondoh 2011).
This study found that global functioning scores at follow-up were
significantly higher in the donepezil group than in the placebo
group (P value = 0.0001). Participants in the donepezil group also
had significantly higher subscale scores of global mental functions,
specific mental functions partial, and voice and speech functions.
There was no difference between the groups for digestive system
function, urinary functions, and movement-related functions.
Behavioural problems
Three studies (157 participants) looked at the impact of donepezil
on behaviour in people with Down syndrome using various scales
(SSIB-R; VABS; ABS; Johnson 2003; Kishnani 2009; Prasher
2002). When combined in a meta-analysis, there was no signif-
icant difference between donepezil and control groups at 12 to
24 weeks postintervention (SMD 0.42, 95% CI -0.06 to 0.89; I²
= 36%; P value for heterogeneity 0.21; τ ² = 0.07; Analysis 1.2).
Using the GRADE approach, this outcome was downgraded from
high to low quality evidence due to imprecision of the effect and
inconsistency of the result.
Daily living skills
None of the four included donepezil studies reported data on daily
living skills.
Adverse events
All four studies (192 participants) looked at the impact of
donepezil on the occurrence of adverse events in peoplewithDown
syndrome (Johnson 2003; Kishnani 2009; Kondoh 2011; Prasher
2002). When combined in a meta-analysis, there was a signifi-
cantly lower rate of adverse events in people receiving placebo,
compared to those receiving donepezil at 12 to 24 weeks postin-
tervention (OR 0.32, 95% CI 0.16 to 0.62; I² = 0%; P value for
heterogeneity 0.93; τ ² = 0.00; Analysis 1.3; Figure 5). Using the
GRADE approach, this outcome was downgraded from high to
low quality evidence due to serious imprecision of the effect.
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Figure 5. Forest plot of comparison: 1 Comparison 1: Donepezil versus placebo, outcome: 1.3 Adverse
events (12 to 24 weeks)
Secondary outcomes
None of the four included donepezil studies reported data on
the secondary outcomes of carer stress, institutional/home care
(including social care placement breakdown), death, or treatment
adherence.
Comparison 2: memantine versus placebo
See Summary of findings 2.
Primary outcomes
Cognitive abilities
Two studies (184 participants) looked at the impact of memantine
on cognitive function in people with Down syndrome using vari-
ous scales (DAMES; DAS-II; Boada 2012; Hanney 2012). When
combined in a meta-analysis, there was no significant difference
between memantine and control groups at 16 to 52 weeks postin-
tervention (SMD 0.05, 95% CI -0.43 to 0.52; I² = 48%; P value
for heterogeneity 0.16; τ ² = 0.06; Analysis 2.1; Figure 6). Using
the GRADE approach, this outcome was downgraded from high
to low quality evidence due to imprecision of the effect and in-
consistency of the result.
Figure 6. Forest plot of comparison: 2 Comparison 2: Memantine versus placebo, outcome: 2.1 Cognitive
abilities (various scales) 16 to 52 weeks
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Global functioning
None of the included memantine studies reported data on global
functioning.
Behavioural problems
Two studies (186 participants) looked at the impact of memantine
on behaviour in people withDown syndrome using different scales
(SIB-R; ABS; Boada 2012; Hanney 2012). When combined in a
meta-analysis, there was no significant difference betweenmeman-
tine and control groups at 16 to 52 weeks postintervention (SMD
-0.17, 95% CI -0.46 to 0.11; I² = 0%; P value for heterogeneity
0.33; τ ² = 0.00; Analysis 2.2). Using the GRADE approach, this
outcome was downgraded from high to low quality evidence due
to serious imprecision of the effect.
Daily living skills
None of the included memantine studies reported data on daily
living skills.
Adverse events
Two studies (211 participants) looked at the impact of memantine
on occurrence of adverse events in people with Down’s syndrome
(Boada 2012; Hanney 2012).When combined in a meta-analysis,
there was no significant difference between donepezil and control
groups at 16 to 52 weeks postintervention (OR0.45, 95%CI 0.18
to 1.17; I² = 0%; P value for heterogeneity 0.47; τ ² = 0.00; Analysis
2.3). Using the GRADE approach, this outcome was downgraded
from high to low quality evidence due to serious imprecision of
the effect.
Secondary outcomes
Neither of the two included memantine studies reported data on
the secondary outcomes of carer stress, institutional/home care
(including social care placement breakdown), death, or treatment
adherence.
Comparison 3: simvastatin versus placebo
One study assessed the effectiveness of simvastatin (Cooper 2012).
Study authors presented results in this study with 90% CIs; a
positive effect size shows benefit from the intervention.
Primary outcomes
Cognitive abilities
As this study was a feasibility and pilot trial, it used an unusually
large number of measurement tools in order to identify the most
appropriate and sensitive measure for use in a full scale trial. Here
we summarize the outcomes from the cognitive test chosen as the
primary measure for a future trial, the Memory for Objects test
from the NADIID battery. The authors choose this as the primary
measure as it had the highest completion rates and was sensitive
to change over time.
Most participants (all but one at baseline and 12-month assess-
ments) completed the measure. Scores at baseline and 12 months
were near the middle of the possible range (zero to 10). Compar-
ison of the baseline and 12-month scores showed a difference be-
tween groups, with improved scores for those in the intervention
group (mean change 1.3; SD 2.7) and a deterioration in scores in
the control group (mean change -0.08; SD 1.2). The effect size,
adjusted for baseline scores, was 0.9 (90% CI 0.4 to 1.4) and ad-
justed for baseline and stratification variables, was 1.0 (90% CI
0.4 to 1.6).
Other cognitive measures piloted were: Selective Attention Can-
cellation Task; Pattern Recognition Memory from the Cambridge
Neuropsychological Test Automated Battery (CANTAB); The
Cats and Dogs Test; Tower of London Test; Cued Recall Test;
Category Fluency; Story Recall (adapted from the Rivermead Be-
havioural Memory Test for Children). These measures had a lower
completion rate.
Global functioning
Cooper 2012 did not assess global functioning.
Behavioural problems
Cooper 2012 did not assess behavioural problems.
Daily living skills
The AAMR: ABS was used to assess adaptive function; this in-
cludes activities of daily living as well as social and conceptual
skills, such as concepts of time and money. The mean change in
the control group was 10 (SD12), while in the intervention group,
the mean change was 2.0 (SD 3.4) with an effect size adjusted
for baseline scores of 0.7 (90% CI -0.1 to 1.3) and adjusted for
baseline and stratification variables of 0.7 (90% CI 0.0 to 1.4).
Adverse events
There were no serious adverse events in the Cooper 2012 trial.
Four participants withdrew from each arm of the trial. The au-
thors’ account of the reasons for withdrawal in the simvastatin
group indicated that all but one withdrawal was due to pre-exist-
ing symptoms (history of episodic diarrhoea, pretrial weight loss),
or withdrawal prior to commencement of medication. One par-
ticipant in the simvastatin group withdrew because of a skin rash.
Secondary outcomes
Carer stress
Only eight of a possible 21 carers completed theGHQ-12measure
of carer strain, and so these results were not reported by the study
authors.
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Institutional/home care (including social care placement
breakdown)
Cooper 2012 did not assess institutional/home care (including
social care placement breakdown).
Death
No deaths occurred in this trial.
Treatment adherence
Two-thirds of participants took the medication for 12 months,
but no information about treatment adherence was provided.
Comparison 4: antioxidants versus placebo
One study assessed the effectiveness of antioxidants (Lott 2011).
Primary outcomes
Cognitive abilities
Changes in cognitive abilities between the intervention and con-
trol groups were very small and indicated that antioxidant supple-
mentation had no effect on the cognitive abilities of participants
in this study. Cognitive abilities were measured using the DMR -
sum of cognitive scores (DMR SOC), the SIB, and the BPT.
The estimated change in the population trajectory (slope) ofDMR
SOC in intervention relative to control groups was a negligi-
ble 0.34 points per half-year (95% CI -1.39 to 2.07). Adjusting
for baseline DMR SOC score made no difference, with one-year
change in DMR SOC in treatment relative to controls of 1.69
points (95% CI -2.92 to 6.31, P value = 0.47). There was no
difference in the average two-year change (3.71 points, 95% CI -
4.81 to 12.22, P value = 0.39).
The estimated change in the population trajectory of the SIB in
the intervention relative to control groups was also very small at
1.10 points per half-year (95% CI -3.40 to 5.59) and was not
statistically significant (P value = 0.63). Adjusting for baseline SIB
score made no difference with one-year change in the intervention
relative to control groups estimated to be -9.08 points (95% CI -
23.86 to 5.70, P value = 0.23) and two-year change estimated to
be -1.51 points (95% CI -13.65 to 10.63, P value = 0.81). Neither
change was statistically significant.
The BPT also detected no statistically significant difference be-
tween intervention and control groups. The estimated change in
the population trajectory (slope) of BPT in intervention relative
to control groups was -1.96 per half-year (95% CI -4.97 to 1.05)
and was not statistically significant (P value = 0.20).
Global functioning
There was no effect of antioxidant supplementation on DMR
SOC scores, which measure the functional domains of speech,
practical skills, mood, activity and interest, as well as behavioural
disturbance over time. Change in the population trajectory in the
intervention group relative to the control group was 0.45 points
per half-year (95% CI -1.67 to 2.56, P value = 0.68), 4.24 for one
year (95% CI -2.10 to 10.58, P value = 0.19), and 4.03 (95% CI
-5.10 to 13.16, P value = 0.39) over two years.
Behavioural problems
The authors did not report results for the maladaptive behaviour
scale of the VABS.
Daily living skills
The Lott 2011 trial found no effect of antioxidant supplementa-
tion on daily living skills. The trial reported that there were no
statistically significant differences between intervention and con-
trol groups on either measure of daily living skills.
Change in the population trajectory of the BADLS score in the
treatment group relative to the control group was 0.46 points per
half-year (95% CI -1.87 to 2.80; P value = 0.70), 3.14 for one
year (95% CI -6.26 to 12.54; P value = 0.51), and 4.82 (95% CI
-4.55 to 14.18; P value = 0.31) over two years.
Change in the population trajectory of the VABS daily living score
in the treatment group relative to the control group was -1.93
points per half-year (95% CI -7.13 to 3.44; P value = 0.48), 0.20
for one year (95% CI-14.01 to 14.40; P value = 0.98), and -13.22
(95% CI -32.17 to 5.72; P value = 0.17) over two years.
Adverse events
Fifty-twoper cent (14out of 26) of those in the intervention group,
and 41% (11 out of 27) in the control group experienced a serious
adverse event (estimated difference was 0.096, 95% CI -0.210
to 0.402; P value < 0.05). These differences were not significant,
and the authors reported that the serious adverse events were not
attributable to the treatment.
A breakdown of the serious adverse events recorded indicated that
seizures were somewhat more common in the intervention group
(12 participants; 44%) versus control group (seven participants;
26%), but the authors attributed this to the higher proportion of
participants with Alzheimer’s disease-associated seizure disorder in
the intervention group (12 out of 27) compared to the control
group (7 out of 26).
Secondary outcomes
Lott 2011 reported no data on the secondary outcomes of carer
stress, institutional/home care (including social care placement
breakdown), or death.
Treatment adherence
Mean treatment adherence from pill counts was 91.9% in the
treatment group and 90.4% in the control group. Elevated plasma
levels of vitamin E after year one and year two in the intervention
group (increase of 103.7% and 87.4% from baseline) compared
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to the control group (increase of 12.6% and 14.9% from baseline)
indicated compliance with the regimen.
Comparison 5: acetyl-L-carnitine versus placebo
One study assessed the effectiveness of acetyl-L-carnitine (Pueschel
2006).
Primary outcomes
This study only provided data on the primary outcomes of cogni-
tive abilities and daily living skills.
Cognitive abilities
Despite listing multiple measures of cognitive functioning,
Pueschel 2006 reported outcomes sparsely, did not provide sum-
mary data, and only mentioned statistical significance at the P
value < 0.05 level. Those outcome measures reported indicated
no statistically significant difference between the intervention and
control groups. The Stanford-Binet Intelligence Scale: Fourth Edi-
tion test of short-term memory, verbal reasoning, abstract/visual
reasoning, quantitative reasoning, and total test score indicated
“no “drug” effect” (p 602). Neither the Mazes and Coding nor
the comprehension subtests from the Wechsler Intelligence Scale
for Children-Revised (WISC-R) showed a “statistically significant
difference between the study and control groups at the end of the
study” (p 602).
The authors reported using the Hiskey-Nebraska Visual Atten-
tion Span and Matching Familiar Figure tests, Seguin Formboard
and the Riddles subtest from the Kaufman Assessment Battery for
Children, but did not report any results that directly related to
these measures. They did, however, indicate that the ’computer
battery’ showed no statistically significant differences between in-
tervention and control groups at the end of the study; this com-
puter battery consisted of tests of continuous performance, verbal
attention span, nonverbal attention span, verbal serial learning,
and paired associates.
Daily living skills
The Daily Living Skills subtest of the VABS self-care skills indi-
cated “no statistically significant difference between the study and
control groups at the end of the study” (p 602).
Adverse events
The authors did notmeasure adverse events explicitly, but did state
that there were no differences between intervention and control
groups in a general physical examination and neurological assess-
ment either at the beginning of the trial or at six months. There
was no indication that these tests were repeated at the nine-month
follow-up.
Authors also stated that all participants tolerated the initial small
doses and “no undue reactions or side effects were observed”.
In addition the authors described a general deterioration in scores
on the Emotional Disorder Rating Scale (EDRS; which was not
listed in the methodology section but was reported in results) in
both groups over time, but with no between-group differences.
The performance of all participants deteriorated over time.
Secondary outcomes
Pueschel 2006 only provideddata on the secondary outcome ’insti-
tutional/home care (including social care placement breakdown)’.
The authors reported that there were no statistically significant
between-group differences in living arrangements, but provided
no quantitative data.
The authors provided no data on the remaining secondary out-
comes: carer stress, death and adherence to treatment.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Comparison 2: memantine versus placebo
Patient or population: people with Down syndrome
Setting: clinic
Intervention: memantine
Comparison: placebo
Outcomes Absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Cognit ive abilit ies
(various scales)
Follow-up: 16 to 52
weeks
- The mean change in
cognit ive abilit ies in
the intervent ion groups
was 0.05 points higher
(0.43 lower to 0.52
higher)
- 184
(2 RCTs)
⊕⊕©©
Low¹
-
Behavioural problems
(various scales)
Follow-up: 16 to 52
weeks
- The mean change in
behavioural problems
the intervent ion groups
was 0.17 points lower
(0.46 lower to 0.11
higher)
- 186
(2 RCTs)
⊕⊕©©
Low²
-
Risk with placebo Risk with memantine - - - -
Adverse events
Follow-up: 16 to 52
weeks
Study populat ion OR 0.45
(0.18 to 1.17)
211
(2 RCTs)
⊕⊕©©
Low²
-
67 per 1000 138 per 1000
(58 to 292)
Moderate
62 per 1000 127 per 1000
(53 to 273)
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Carer stress No data available No data available - - - -
Inst itut ional/ home care No data available No data available - - - -
Death No data available No data available - - - -
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI)
CI: conf idence interval; GRADE: Grades of Recommendations, Assessment, Development and Evaluat ion; OR: odds rat io; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded two levels due to imprecision (wide conf idence intervals) and inconsistency (I² = 48%).
2Downgraded two levels for serious imprecision (wide conf idence interval) and small number of events.
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D I S C U S S I O N
Summary of main results
Following an extensive systematic search, we identified only nine
studies that met the eligibility criteria for this review. These studies
assessed five different types of pharmacological interventions, each
against placebo:
1. donepezil;
2. memantine;
3. simvastatin;
4. antioxidants;
5. acetyl-L-carnitine.
Donepezil
There is currently insufficient evidence to determine whether
donepezil is effective in treating cognitive decline in people with
Down syndrome.
Results suggest that scores in measures of cognitive functioning
and measures of behaviour were similar for participants regard-
less of whether they received donepezil or placebo. There is lim-
ited evidence that those who received donepezil may have shown
a slightly greater improvement in their global functioning. Fur-
thermore, participants who received donepezil were significantly
more likely to experience an adverse event. This indicates that this
intervention may be associated with a lack of any clear benefit, as
well as a risk of side effects.
We found the evidence for most outcomes to be of low quality,
primarily due to imprecise results and statistical heterogeneity.
Memantine
There is currently insufficient evidence to determine whether me-
mantine is effective in treating cognitive decline in people with
Down syndrome.
Results suggest that scores in measures of cognitive functioning
and measures of behaviour were similar for participants regardless
of whether they receivedmemantine or placebo. There was also no
difference in the rate of adverse events experienced by participants
who received memantine and those who received placebo.
We found the evidence for most outcomes to be of low quality,
primarily due to imprecise results and statistical heterogeneity.
Simvastatin
There is currently insufficient evidence to determine whether sim-
vastatin is effective in treating cognitive decline in people with
Down syndrome.
Only one eligible study was found that assessed the effectiveness
of this intervention. Results from this feasibility study suggest that
the six participants who received simvastatin experienced a slight
improvement on cognitive measures, whereas the seven partici-
pants in the control group experienced a slight decline in cognitive
measures, but little can be concluded from this small trial. There
were no serious adverse events reported for any participant.
Antioxidants
There is currently insufficient evidence to determine whether an-
tioxidants are effective in treating cognitive decline in people with
Down syndrome.
We found only one eligible study that assessed the effectiveness of
this intervention. Results from this study suggested that there was
no difference between groups for cognition, global functioning,
daily living skills, or occurrence of adverse events.
Acetyl-L-carnitine
There is currently insufficient evidence to determine whether
acetyl-L-carnitine is effective in treating cognitive decline in peo-
ple with Down syndrome.
We found only one eligible study that assessed the effectiveness of
this intervention. Results from this study suggest that there was
no difference between participants who received acetyl-L-carnitine
and those who received placebo on measures of cognitive abilities,
behavioural problems, daily living skills, occurrence of adverse
events, or living arrangements.
Overall completeness and applicability of
evidence
Our extensive search for RCTs for pharmacological interventions
for cognitive decline in people with Down syndrome identified
only four studies of donepezil, two studies of memantine, and one
study each of simvastatin, antioxidants, and acetyl-L-carnitine.
We found no relevant studies that assessed the effectiveness
of galantamine, rivastigmine, piracetem, or DYRK1A inhibitors
(green tea extract) in people with Down syndrome. Therefore, this
review is not able to provide any indication of whether these in-
terventions are effective forms of treatment for cognitive decline
in people with Down syndrome. We identified two ongoing stud-
ies that are assessing the effectiveness of vitamin supplementation,
and ELND005 (scyllo-inositol) treatment. It is likely that the ef-
fectiveness of these interventions will be included in the next up-
date of this review.
Eight of the nine included studies were conducted (entirely or
partially) in either theUK, or theUSA, whichmay limit the extent
to which these results can be applied internationally.
The authors of Hanney 2012 (memantine trial) noted that when
recruiting for this trial, they specifically excluded people with se-
vere dementia. Since memantine is thought to deliver the greatest
benefit in people with moderate-to-severe dementia, it is possible
that it could provide a benefit for individualswithDown syndrome
who have more severe dementia. However this possibility requires
further exploration in clinical trials before any reliable conclusions
can be drawn.
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Quality of the evidence
All of the included studies were at a relatively low risk of bias.
Most were clear and explicit in their methods of allocation and
blinding. However, their risks of bias across a number of other
domains were difficult to judge on the basis of the information
provided in the published paper only. Their selection of outcomes
and presentation of outcome data in particular may have been
subject to bias, but without confirmation from the study authors,
we could only judge them as being at ’unclear’ risk of bias.
The overall quality of the evidence of this review was judged to be
low. This was primarily due to the small number of participants
and events that could be incorporated into any pooled analysis,
leading to imprecise results, and the high levels of statistical het-
erogeneity indicated across many of the pooled analyses.
Potential biases in the review process
We made every attempt to follow the protocol of this review, thus
minimising our risk of bias in the review process. Despite an ex-
tensive systematic search, we identified only nine studies that met
the inclusion criteria and could be included in the synthesis. Al-
though one study did appear to fit the eligibility criteria for this
review (Eisenburg 1984), the decision was made to omit it from
the overall synthesis of the review, as data could not be obtained
for participants aged 18 years and older only. Also, we judged a
small number of domains in the ’Risk of bias’ assessment for some
included studies as ’unclear’.We have contacted study authors and
asked for clarification on these issues, but we have not received
any confirmation prior to publication.
Agreements and disagreements with other
studies or reviews
To date, there have been four published Cochrane Systematic
Reviews that have focused on the use of various pharmaco-
logical interventions in Down syndrome, including donepezil
(Mohan 2009a), galantamine (Mohan 2009b), memantine (
Mohan 2009c), and rivastigmine (Mohan 2009d). Across all four
reviews, the review authors found only one small randomised trial
of donepezil that was eligible for inclusion. This study is included
in our review, together with a study of memantine (Hanney 2012),
which was listed as an ’Ongoing study’ in the previous meman-
tine review (Mohan 2009c). No ongoing studies were identified in
the earlier galantamine (Mohan 2009b), or rivastigmine reviews
(Mohan 2009d), and this situation remains unchanged.
Overall, the results of our review are in agreement with the find-
ings of these four previous review, in that there continues to be
insufficient evidence that any one of these drugs could slow the
rate of cognitive decline in this population.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to the low sample size of the included studies in this review,
it is difficult to state with certainty the implications for the con-
tinued practice of pharmacological interventions for cognitive de-
cline in people with Down syndrome. Donepezil may be associ-
ated with a lack of any clear benefit, as well as a risk of adverse
events. There is limited and inconclusive evidence for meman-
tine, antioxidants and acetyl-L-carnitine. The results fromCooper
2012 suggest there may be a positive trend for participants receiv-
ing simvastatin, but this suggestion is based only on preliminary
results from a small feasibility study. There are no data available
to consider the impact of galantamine, rivastigmine, piracetem, or
DYRK1A inhibitors for cognitive decline in people with Down
syndrome.
Implications for research
This review highlights the need for further research in this area.
More RCTs are needed before any conclusions can be drawn about
the effectiveness of any pharmacological intervention for treating
cognitive decline in people with Down syndrome. Future research
should also provide clear details regarding the inclusion criteria
for participants, and in particular, the level of dementia they con-
sider eligible and ineligible for their studies. It is also important
to consider the reasons why this review identified so few eligible
RCTs, and why these RCTs have such small sample sizes. This
could be a reflection of the fact that it is difficult to conduct re-
search in this population. Scoping of potential sample size should
be an important priority for commissioning of future research in
this area. Furthermore, future research should consider the choice
of outcomes to be measured carefully. For example, only two of
the included studies reported global functioning, which some con-
sider a more reliable measure of outcome in this population than
cognitive function. In addition, researchers must ensure that any
measurement tools selected are likely to be completed by partici-
pants, sufficiently sensitive to detect relevant changes, harmonised
so that meta-analysis can be undertaken and sufficiently powered.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boada 2012
Methods Randomised, double-blinded, placebo-controlled trial
Participants • 40 participants randomised (20 intervention, 20 control)
• ◦ 1 (control) participant declined participation for personal reasons
◦ 1 (intervention) participant discontinued due to adverse events
◦ 1 (intervention) participant excluded from analyses due to adverse events
• 37 participants included in primary analysis
• Mean age of participants: 23.27 years intervention, 22.60 years control
• Gender of participants: 14 males (7 intervention, 7 control), 24 females (12
intervention, 12 control)
Interventions Intervention group
• Memantine: 5 mg once daily during week 1, 5 mg twice daily during week 2, 5
and 10 mg daily (divided dose = 15 mg) during week 3, and 10 mg twice daily from
week 4 to week 16
Control group
• “placebo tablets (containing the same fillers and binders as the memantine tablets,
but no active ingredients)”
Outcomes • Cognitive function (DAS II Matrices)
• Behaviour (SIB-R)
Duration of follow-up: 16 weeks
Notes Although 3 participants were missing from the primary analysis, the review authors
agreed that because Boada used repeated measures mixed models, which already takes
account of dropouts (which were balanced in the 2 arms), it was not necessary to impute
these missing data into our pooled analyses
Clinical Trials.Gov Identifier: NCT01112683
Funded by: Forest Research Institute Investigator Initiated Grant NAM-58
Study start date: July 2008
Study end date: August 2011
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk No information was provided beyond “par-
ticipants were randomized”. Authors were
contacted for further information, and they
replied confirming “Assignment of sub-
jects to memantine or placebo was per-
formed according to a computerized ran-
domization schedule commissioned to Ja-
son Child, PharmD., then, the head phar-
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Boada 2012 (Continued)
macist at the Investigational Drug Ser-
vices at the Children’s Hospital Colorado”
(Costa 2015, pers comm in Boada 2012)
Allocation concealment (selection bias) Low risk Quote: “Dr. Child was the only one with
access to the key for the double-blind la-
bels” “Dr. Child had no direct contact with
any of the physicians or psychologists per-
forming safety or efficacy assessments dur-
ing this trial” (Costa 2015, pers comm in
Boada 2012)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “participants, caregivers and all
other investigators were blind to the treat-
ment allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “participants, caregivers and all
other investigators were blind to the treat-
ment allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk This study used repeated measures mixed
models, which already takes account of
dropouts (which were balanced in the 2
arms)
Selective reporting (reporting bias) Low risk All outcomes specified in the protocol were
reported
Other bias Low risk Quote: “This trial was funded by Forest Re-
search Institute Investigator InitiatedGrant
NAM-58. ACSC was also supported in
part by NIH Grant RO1-HD056235, the
Linda Crnic Institute and the Coleman In-
stitute forCognitiveDisabilities. The fund-
ing sources had no role in the design and
conduct of the study; in the collection,
analysis and interpretation of the data; or in
the preparation, review or approval of the
manuscript”
Cooper 2012
Methods Randomised, double-blinded, placebo-controlled trial
Participants • 21 participants randomised (10 Intervention, 11 control)
◦ 4 participants lost from each arm
• 13 participants included in final analysis (6 Intervention, 7 control)
• Mean age of participants: 54.68 years intervention, 53.67 years control
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Cooper 2012 (Continued)
• Gender of participants: 11 males (5 intervention, 6 control), 10 females (5
intervention, 5 control)
Interventions Intervention group
• Simvastatin 40 mg once daily
Control group
• Placebo
Outcomes • Cognitive decline (NADIID)
• Daily living skills (AAMR: ABS)
• Carer stress (GHQ-12)
Duration of follow-up: 52 weeks
Notes ICTRP Identifier: ISRCTN67338640
Funded by: The Chief Scientist Office, Scottish Government Health Department (ref-
erence: CZH/4/626)
Study start date: April 2012
Study end date: March 2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly assigned by Robert-
son Centre for Biostatistics (RCB)
Allocation concealment (selection bias) Low risk Randomisation was carried out by Robert-
son Centre for Biostatistics (RCB), who in-
formed the pharmacy of each participant’s
medication pack number assigned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The research team will therefore
remain blinded to group allocation status,
as will the participants and their caregivers”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The research team will therefore
remain blinded to group allocation status,
as will the participants and their caregivers”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 participants lost to follow-up from each
arm (4/11 and 4/10). Given that the drop-
outs were balanced, it is unlikely that this
introduced bias
Selective reporting (reporting bias) Low risk All outcomes specified in the protocol were
reported
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Cooper 2012 (Continued)
Other bias Low risk Quote: “This study is funded by the Chief
Scientist Office, Scottish Government
Health Department (reference: CZH/4/
626). JS is funded by theNHSLothian R&
D Directorate”
Hanney 2012
Methods Randomised, double-blinded, placebo-controlled trial
Participants • 173 participants randomised (88 intervention; 85 control)
◦ Of these, 31 (35%) intervention participants and 30 (35%) control
participants had a baseline diagnosis of dementia
• Mean age of participants: 51.7 years intervention, 51.0 years control
• Gender of participants: 98 males (50 intervention, 48 control), 75 females (38
intervention, 37 control)
Interventions Intervention group
• Memantine: 2 tablets per day for 52 weeks; dosage began at 5 mg for 8 weeks,
then increased to 10 mg with fixed titration
Control group
• Placebo as identical scored tablets
Outcomes • Attention, memory and executive function, as measured by DAMES
• Adaptive behaviour, as measured by AAMR: ABS
Duration of follow-up: 52 weeks
Notes Clinical Trials.Gov Identifier: NCT00240760
ICTRP Identifier: ISRCTN47562898
Funded by: Lundbeck (Valby, Denmark)
Study start date: July 2005
Study end date: July 2006
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated using a “computer-
generated allocation sequence”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was done by a
statistician (NW) at the Centre for Statis-
tics in Medicine (Oxford, UK) who allo-
cated treatment and distributed pack num-
bers to the pharmacist, ensuring masking
of participants and investigators and allo-
cation concealment”
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Hanney 2012 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Memantine and placebo were pro-
vided as identical scored tablets to ensure
that the memantine and placebo could not
be distinguished”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Ethics committee was “the only body who
had access to unmasked data”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study analysed and presented the data
available for each outcome. Study also in-
cluded a “posthoc sensitivity analysis with
multiple imputation method to handle
missing data”
Selective reporting (reporting bias) High risk Quality of life (QOL-AD) and post-test in-
cidence of dementia planned in protocol
but not reported in paper. DAMES and
AAMR: ABS reported for dementia sub-
group only. Study authors were emailed to
clarify this issue - no reply as of 15 Septem-
ber 2015
Other bias Low risk Study was funded by Lundbeck (Valby,
Denmark) as an investigator-led trial
Johnson 2003
Methods Randomised, double-blinded, placebo-controlled study
Participants • 19 participants randomised (10 intervention, 9 control)
◦ 1 participant lost to follow-up
• 18 participants in final analyses (9 intervention, 9 control)
• Mean age of participants: 29.5 years intervention, 24.7 years control
• Gender of participants: 11 males (4 intervention, 7 control), 8 females (6
intervention, 2 control)
Interventions Intervention group
• Donepezil: 5 mg/day for first 6 weeks then 10 mg/day for the remaining 6 weeks
Control group
• Placebo
Outcomes • Cognitive functioning (SCIP)
• Behaviour (SIB-R)
• Global functioning (SIB-R)
• Adverse events
Duration of follow-up: baseline, 4 weeks and 12 weeks
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Johnson 2003 (Continued)
Notes Funded by: Pfizer grant to N Johnson and Northwestern Alzheimer’s Disease Center,
Grant AG 13854 from NIA
Study start/end date: 2002
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by medical school pharmacy
Allocation concealment (selection bias) Low risk Randomised by medical school pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “neither the researchers nor the par-
ticipants were aware of subject groupmem-
bership (donepezil vs. placebo) until the
study was completed”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “neither the researchers nor the par-
ticipants were aware of subject groupmem-
bership (donepezil vs. placebo) until the
study was completed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in anal-
yses
Selective reporting (reporting bias) Low risk All relevant measures appear to have been
reported
Other bias Unclear risk Quote: “This work was supported by the
following sources: Pfizer grant to N. John-
son and Northwestern Alzheimer’s Disease
Center, Grant AG 13854 from NIA”. Re-
port did not state whether the funder was
involved in any aspect of the study
Kishnani 2009
Methods Randomised, double-blinded, placebo-controlled study
Participants • 123 participants randomised (62 intervention, 61 control)
◦ 3 participants discontinued treatment
• 120 participants in final analyses (59 intervention, 61 control)
• Mean age of participants: 24.2 years intervention, 26.0 years control
• Gender of participants: 77 males (38 intervention, 39 control), 46 females (24
intervention, 22 control)
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Kishnani 2009 (Continued)
Interventions Intervention
• Donepezil: 5 mg/day for 6 weeks followed by 10 mg/day for 6 weeks
Control
• Placebo
Outcomes • Cognitive functioning (SIB)
• Behaviour (VABS)
• Adverse events
Duration of follow-up: 12 weeks
Notes A very small proportionof the participants (3/123)were not included in the final analyses.
Given that the dropouts were balanced, it is unlikely that this introduced bias. Therefore,
the review authors agreed it was not necessary to impute these missing data into our
pooled analyses
Funded by: Eisai, Inc and Pfizer, Inc
Study start/end date: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided beyond partici-
pants were “randomly assigned”. Authors
were contacted for more information, but
have not yet replied as of 15 September
2015
Allocation concealment (selection bias) Unclear risk No information provided beyond partici-
pants were “randomly assigned”. Authors
were contacted for more information, but
have not yet replied as of 15 September
2015
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote “double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote “double-blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants who discontinued treatment
were not included in the analyses. Given
that the dropouts were balanced, it is un-
likely that this introduced bias
Selective reporting (reporting bias) Unclear risk A protocol could not be obtained for this
study. Authors were contacted for more in-
formation, but have not yet replied as of 15
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Kishnani 2009 (Continued)
September 2015
Other bias Unclear risk Quote: “This study was sponsored by Eisai,
Inc. and Pfizer, Inc”. Report did not state
whether the funder was involved in any as-
pect of the study
Kondoh 2011
Methods Randomised, double-blinded, placebo-controlled study
Participants • 21 participants randomised (11 intervention, 10 control)
• 21 participants in final analysis (11 intervention, 10 control)
• Mean age of participants: 45.6 years (breakdown for intervention and control
groups not provided)
• Gender of participants: 100% female
Interventions Intervention group
• Donepezil: 3 mg/day for 24 weeks
Control group
• Placebo: 600 mg sucrose
Outcomes • Global functioning (ICF)
• Adverse events
Duration of follow-up: 24 weeks
Notes Funded by: unknown
Study start date: 2006
Study end date: 2007
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided beyond “sim-
ple random sampling”. Authors were con-
tacted for more information, but have not
yet replied as of 15 September 2015
Allocation concealment (selection bias) Low risk Quote: “list of allocation kept securely in
the pharmacy ... not available to anyone
except Mna, who never had contact with
patients”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “placebo and drug identically sup-
plied and formulated”
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Kondoh 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Code not disclosed until analysis
completed and fixed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in the
analyses
Selective reporting (reporting bias) Unclear risk A protocol could not be obtained for this
study. Authors were contacted for more in-
formation, but have not yet replied as of 15
September 2015
Other bias Low risk None known
Lott 2011
Methods Randomised, double-blinded, placebo-controlled study
Participants • 58 participants randomised (29 intervention, 29 control)
◦ 5 participants discontinued treatment
• 53 participants in final analyses (27 intervention, 26 control)
• Mean age of participants: 50.65 years intervention, 50.63 years control
• Gender of participants: 25 males (15 intervention, 10 control), 28 females (11
intervention, 17 control)
Interventions Intervention group
• Antioxidant: 900 IU of alpha-tocopherol, plus 200 mg of ascorbic acid plus 600
mg of alpha-lipoic acid. This daily dose was taken as 1 capsule at breakfast and 2
capsules at the evening meal for 24 months
Control group
• Placebo
Outcomes • Cognitive functioning (SIB)
• Behaviour (VABS)
• Daily living skills (BADLS)
• Adverse events
Duration of follow-up: 1-year interim and 2-year final follow-up
Notes Grant sponsor: NIA; Grant numbers: AG-21912, ADRC P50-AG16573; “My Brother
Joey” Neuroscience Fund
Study start date: June 2003
Study end date: May 2008
Risk of bias
Bias Authors’ judgement Support for judgement
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Lott 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “(computerized random numbers)
was used to assign participants to either the
treatment or placebo group”
Allocation concealment (selection bias) Low risk Quote: “The allocation sequence was con-
cealed from participants and all members
of the research team for the entire duration
of the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The antioxidant supplements for
the treatment group were manufactured in
capsule form and were identical in appear-
ance to the placebo capsules”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The allocation sequence was con-
cealed from participants and all members
of the research team for the entire duration
of the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for in the
analyses
Selective reporting (reporting bias) Low risk A protocol was obtained from the authors
of this study. All expected outcomes were
reported
Other bias Low risk None known
Prasher 2002
Methods Randomised, double-blinded, placebo-controlled trial
Participants • 31 participants randomised (16 intervention; 15 control)
◦ 1 control participant went into hospital at the point of randomisation and
therefore did not begin the intervention
◦ In total, 16 intervention and 14 control participants began treatment
• All participants had an ICD-10 diagnosis of dementia
• Mean age of participants: 53.06 years intervention, 55.07 years control
• Gender of participants: 15 males (10 intervention, 5 control), 15 females (6
intervention, 9 control)
Interventions Intervention group
• Donepezil: 1 tablet per day for 24 weeks; dosage began at 5 mg for 4 weeks, then
increased to 10 mg (3 in drug group remained at 5 mg per day due to side effects)
Control group
• Placebo tablets similar in colour, shape, and size
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Prasher 2002 (Continued)
Outcomes • Global functioning (intellectual, social and behavioural; DMR)
• Cognitive function (SIB)
• Non-cognitive and behavioural psychopathology (NPI)
• Adaptive behaviour (AAMR: ABS)
• Adverse events
• Caregiver views, as measured by a qualitative questionnaire designed by the
authors specifically for the study
Duration of follow-up: 24 weeks
Notes A very small proportion of the participants (3/30)may not have been included in the final
analyses. Given that the dropouts were balanced, it is unlikely that this introduced bias.
Therefore, the review authors agreed it was not necessary to impute these missing data
into our pooled analyses. A follow-up open label study to this trial was conducted using
a cross-over design and published in 2003 (Prasher 2003). We have not analysed data
for the follow-up period because this study was carried out on an open-label basis. All
risk of bias judgements are based on the original randomised, double-blinded, placebo-
controlled trial
Clinical Trials.Gov Identifier: NCT00240760
Funded by: Pfizer and Eisai
Study start date: October 2005
Study end date: not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Names of individuals were put
into separate sealed envelopes, shuffled and
then the first envelope (one person) was al-
located to the active group, and the next
to the placebo group ... and so on until all
individuals were allocated”
Allocation concealment (selection bias) Unclear risk Quote: “Names of individuals were put
into separate sealed envelopes”. Study au-
thors emailed to confirm that envelopes
were opaque and sequentially numbered.
Authors replied (9 September 2015) stat-
ing it would not be possible to obtain the
information requested
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “patients, carers and the researcher
undertaking data collection were blind
throughout the study period”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “patients, carers and the researcher
undertaking data collection were blind
throughout the study period”. VP (Princi-
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Prasher 2002 (Continued)
ple investigator) had to break the alloca-
tion code after some patients suffered side
effects but was not involved in outcome
assessment. Quote: “other researchers, pa-
tients, cares and data analysis remained
blind until the study was completed”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether analyses based on 30 ran-
domised or 27 at follow-up. We emailed
the authors to request confirmation. Au-
thors replied (9 September 2015) stating it
would not be possible to obtain the infor-
mation requested
Selective reporting (reporting bias) Unclear risk No protocol available. We emailed the
authors to request confirmation that all
planned outcomes were measured and
reported. Authors replied (9 September
2015) stating it would not be possible to
obtain the information requested
Other bias Low risk Sponsored by Pfizer and Eisai via an “un-
restricted educational grant”. This implies
that the sponsor did not have involvement
in the trial or influence over the content of
reports
Pueschel 2006
Methods Randomised, double-blinded, placebo-controlled trial
Participants • 40 participants randomised (20 intervention; 20 control)
• Number included in final analysis not known
• Mean age of participants: 20.2 years intervention, 21.5 years control
• Gender of participants: 100% male
Interventions Intervention group
• Acetyl-L-carnitine: 10 mg/kg/day divided into 3 doses during the first month.
Increased to 20 mg/kg/day in second month and afterwards to 30 mg/kg/day for the
rest of the study
Control group
• Placebo tablet, with similar appearance and taste
Outcomes • Cognitive function (SBIS)
• Behavioural problems (CBCL)
• Daily living skills (VABS)
• Adverse events
Duration of follow-up: baseline, 3, 6 and at 9 months, after a 3-month ‘washout’ period
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Pueschel 2006 (Continued)
Notes Authors were contacted to enquire about final numbers analysed. No response at time
of publication
Funded by: unknown
Study start/end date: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “An independent statistical consul-
tant randomly assigned the persons with
Down syndrome to either the study or con-
trol group”
Allocation concealment (selection bias) Low risk Quote: “An independent statistical consul-
tant randomly assigned the persons with
Down syndrome to either the study or con-
trol group”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The evaluators, parents, and the
subjects with Down syndrome were blind
relative to group assignment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The evaluators, parents, and the
subjects with Down syndrome were blind
relative to group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information given on final numbers
analysed
Selective reporting (reporting bias) High risk The overall reporting of the resultswas poor
and there were discrepancies between what
was measured according to the methodol-
ogy and what was presented in the results.
This paper provided little detail on out-
comes, published no numerical data at all,
and did not report on outcomes that au-
thors listed as outcome measures and did
report on outcomes not mentioned in the
methods section
Other bias Low risk None known
AAMR: ABS - American Association of Mental Retardation: Adaptive Behavior Scale
BADLS - Bristol Activities of Daily Living Scale
CBCL - Child Behavior Checklist
CGIC - Clinical Global Impression of Change
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DAMES - Down Syndrome Attention Memory and Executive Function Scale
DAS-II - Differential Ability Scales-II
DMR - Dementia Questionnaire for Persons with Mental Retardation
GHQ-12 - General Health Questionnaire 12
ICD-10 - International Classification of Diseases, 10th Revision
ICF - International Classification of Functioning, Disability and Health scales
NADIID - Neuropsychological Assessment of Dementia in Intellectual Disabilities Battery
NHS - National Health Service
NIH - National Institute of Health
NPI - Neuropsychiatric Inventory
QoL-AD - Quality of Life in Alzheimer’s Disease
SBIS - Stanford-Binet Intelligence Scale: 4th Edition
SCIP - Severe Cognitive Impairment Profile
SIB - Severe Impairment Battery
SIB-R - Scales of Independent Behavior-Revised
VABS - Vineland Adaptive Behavior Scales
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arvat 1996 Focus of the study was on comparing the effect of pyridostigmine in participants with Down syndrome to
those without Down syndrome
Barr 1990 Paper was an overview of the current state of evidence and provided no evaluation or new data
Boada-Rovira 2005 Paper was an overview of the current state of evidence and provided no evaluation or new data
Breeze 2012 Paper was an overview of the current state of evidence and provided no evaluation or new data
De Falco 1994 Focus of the study was on comparing the effect of acetyl-L-carnitine treatment in participants with Down
syndrome to those without Down syndrome
Gedye 1991 Study made use of a single case study design, and its focus was on aggression rather than cognitive decline
Lobaugh 2001 Study on children under 18 years of age
Pueschel 1980 Study on children under 18 years of age
Schill 2005 Not a randomised controlled trial
Shinagawa 2014 Paper was an overview of the current state of evidence and provided no evaluation or new data
Thase 1982 Study made use of a single case study design, and its focus was on aggression rather than cognitive decline
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Characteristics of ongoing studies [ordered by study ID]
Aisen 2005
Trial name or title Multicenter vitamin E trial in aging persons with Down syndrome
Methods RCT
Participants • 349 participants reported on clinical trial register
• In the 2005 publication, researchers indicated that at that time 316 participants (162 women, 154
men) with Down syndrome had been recruited. Aged between 33 and 77 years (mean 48.7 years; SD 6.2
years)
• Degree of intellectual disability was available for 262 participants
◦ 39 (15%) classified as mild
◦ 137 (52%) classified as moderate
◦ 75 (29%) classified as severe
◦ 11 (4%) classified as profound
• Information on dementia status was available for 98 participants
◦ 57 (58%) recorded as ’no dementia’
◦ 41 (42%) with a diagnosis of probable dementia
Interventions Vitamin E (alpha-tocopherol)
• 1000 IU synthetic vitamin E twice daily or identical placebo
Outcomes Primary
• Change in BPT score
Secondary
• CGIC
• New Dot Test
• Modified Fuld test
• Vocabulary Test
• Behavior and Function Questionnaire
• Time to diagnosis of Alzheimer’s disease (in non-demented participants)
Starting date September 2000
Contact information mary.sano@mssm.edu
Notes According to ClinicalTrials.gov the primary completion date of this study was April 2010
Authors have been contacted for data and they responded advising that they are “in a revision” which they
“hope will be done soon”
ClinicalTrials.govidentifier: NCT01594346
NCT01791725
Trial name or title A 4-week randomized, double-blinded, placebo-controlled, phase 2a safety and PK study of oral ELND005
(scyllo-inositol) in young adults with Down syndrome without dementia
Methods Randomised, double-blinded, placebo-controlled, parallel-group, 3-arm trial
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NCT01791725 (Continued)
Participants Inclusion criteria
• 18 to 45 years of age
• IQ of > 40 (K-BIT)
• Able and willing to have a brain MRI
Exclusion criteria
• Symptoms of dementia or worsening cognition over the past year
• History of hepatitis B, hepatitis C, or HIV
Interventions • Experimental (arm 1): ELND005 (scyllo-inositol) 250 mg, twice daily
• Experimental (arm 2): ELND005 (scyllo-inositol) 250 mg, once daily
• Control (arm 3): placebo twice daily
Outcomes • Incidence of adverse events
• Changes from baseline in physical and neurological examinations
• Plasma ELND005 concentrations
• ELND005 PK profile to optimise PK model, including patient population
• Cognitive outcome
• Rapid Assessment for Development Disabilities (RADD) functional outcomes
• Vineland Adaptive Behavior Scale, Second Edition (VABS-II)
Starting date September 2013
Contact information None provided. Information provided by (Responsible Party): Transition Therapeutics Ireland Limited
Notes According to ClinicalTrials.gov, the primary completion date of this study was June 2014
The Responsible Party (Transition Therapeutics Ireland Limited) have been contacted for data and have not
yet replied
ClinicalTrials.gov identifier: NCT01791725
BPT - Brief Praxis Test
CGIC - Clinical Global Impression of Change
HIV - human immunodeficiency virus
IQ - intelligence quotient
K-BIT-2 - Kaufman Brief Intelligence Test, 2nd Edition
MRI - magnetic resonance imaging
PK - pharmacokinetic
RCT - randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Comparison 1: donepezil versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cognitive abilities (Severe
Impairment Battery) 12 to 24
weeks
3 165 Std. Mean Difference (IV, Random, 95% CI) 0.52 [-0.27, 1.31]
2 Behavioural problems (various
scales) 12 to 24 weeks
3 157 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.06, 0.89]
3 Adverse events (12 to 24 weeks) 4 192 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.16, 0.62]
Comparison 2. Comparison 2: memantine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cognitive abilities (various
scales) 16 to 52 weeks
2 184 Std. Mean Difference (IV, Random, 95% CI) 0.05 [-0.43, 0.52]
2 Behavioural problems (various
scales) 16 to 52 weeks
2 186 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.46, 0.11]
3 Adverse events (16 to 52 weeks) 2 211 Odds Ratio (M-H, Random, 95% CI) 0.45 [0.18, 1.17]
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Analysis 1.1. Comparison 1 Comparison 1: donepezil versus placebo, Outcome 1 Cognitive abilities (Severe
Impairment Battery) 12 to 24 weeks.
Review: Pharmacological interventions for cognitive decline in people with Down syndrome
Comparison: 1 Comparison 1: donepezil versus placebo
Outcome: 1 Cognitive abilities (Severe Impairment Battery) 12 to 24 weeks
Study or subgroup Donepezil Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Johnson 2003 9 2.25 (3.52) 9 -0.28 (0.39) 26.7 % 0.96 [ -0.03, 1.95 ]
Kishnani 2009 59 1.2 (5.87) 61 1.6 (5.87) 42.1 % -0.07 [ -0.43, 0.29 ]
Prasher 2002 14 31.6 (28.2) 13 11.2 (8.7) 31.2 % 0.93 [ 0.13, 1.73 ]
Total (95% CI) 82 83 100.0 % 0.52 [ -0.27, 1.31 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 7.62, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours donepezil
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Analysis 1.2. Comparison 1 Comparison 1: donepezil versus placebo, Outcome 2 Behavioural problems
(various scales) 12 to 24 weeks.
Review: Pharmacological interventions for cognitive decline in people with Down syndrome
Comparison: 1 Comparison 1: donepezil versus placebo
Outcome: 2 Behavioural problems (various scales) 12 to 24 weeks
Study or subgroup Donepezil Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Johnson 2003 9 84.22 (7.86) 9 85 (13.88) 19.9 % -0.07 [ -0.99, 0.86 ]
Kishnani 2009 53 3.4 (8.01) 59 0.6 (8.45) 55.7 % 0.34 [ -0.04, 0.71 ]
Prasher 2002 14 120.5 (44.1) 13 84.5 (22.4) 24.4 % 0.99 [ 0.18, 1.79 ]
Total (95% CI) 76 81 100.0 % 0.42 [ -0.06, 0.89 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 3.11, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours donepezil
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Analysis 1.3. Comparison 1 Comparison 1: donepezil versus placebo, Outcome 3 Adverse events (12 to 24
weeks).
Review: Pharmacological interventions for cognitive decline in people with Down syndrome
Comparison: 1 Comparison 1: donepezil versus placebo
Outcome: 3 Adverse events (12 to 24 weeks)
Study or subgroup Donepezil Placebo
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Johnson 2003 0/9 0/9 Not estimable
Kishnani 2009 46/62 29/61 76.4 % 0.32 [ 0.15, 0.67 ]
Kondoh 2011 2/11 1/10 6.6 % 0.50 [ 0.04, 6.55 ]
Prasher 2002 8/16 3/14 17.0 % 0.27 [ 0.05, 1.36 ]
Total (95% CI) 98 94 100.0 % 0.32 [ 0.16, 0.62 ]
Total events: 56 (Donepezil), 33 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 3.39 (P = 0.00069)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours donepezil
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Analysis 2.1. Comparison 2 Comparison 2: memantine versus placebo, Outcome 1 Cognitive abilities
(various scales) 16 to 52 weeks.
Review: Pharmacological interventions for cognitive decline in people with Down syndrome
Comparison: 2 Comparison 2: memantine versus placebo
Outcome: 1 Cognitive abilities (various scales) 16 to 52 weeks
Study or subgroup Memantine Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Boada 2012 19 3.39 (9.7) 19 -0.32 (9.44) 34.7 % 0.38 [ -0.26, 1.02 ]
Hanney 2012 72 -5.6 (34.6) 74 -1.9 (19.5) 65.3 % -0.13 [ -0.46, 0.19 ]
Total (95% CI) 91 93 100.0 % 0.05 [ -0.43, 0.52 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours memantine
Analysis 2.2. Comparison 2 Comparison 2: memantine versus placebo, Outcome 2 Behavioural problems
(various scales) 16 to 52 weeks.
Review: Pharmacological interventions for cognitive decline in people with Down syndrome
Comparison: 2 Comparison 2: memantine versus placebo
Outcome: 2 Behavioural problems (various scales) 16 to 52 weeks
Study or subgroup Memantine Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Boada 2012 19 5.94 (9.84) 19 4.88 (9.23) 20.5 % 0.11 [ -0.53, 0.75 ]
Hanney 2012 75 -10.7 (37.1) 73 -1.7 (35.1) 79.5 % -0.25 [ -0.57, 0.08 ]
Total (95% CI) 94 92 100.0 % -0.17 [ -0.46, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours memantine
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Analysis 2.3. Comparison 2 Comparison 2: memantine versus placebo, Outcome 3 Adverse events (16 to
52 weeks).
Review: Pharmacological interventions for cognitive decline in people with Down syndrome
Comparison: 2 Comparison 2: memantine versus placebo
Outcome: 3 Adverse events (16 to 52 weeks)
Study or subgroup Memantine Placebo
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boada 2012 4/19 1/19 17.1 % 0.21 [ 0.02, 2.07 ]
Hanney 2012 11/88 6/85 82.9 % 0.53 [ 0.19, 1.51 ]
Total (95% CI) 107 104 100.0 % 0.45 [ 0.18, 1.17 ]
Total events: 15 (Memantine), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours memantine
A D D I T I O N A L T A B L E S
Table 1. Levels of quality of a body of evidence in the GRADE approach
Underlying methodology Quality rating
Randomized trials; or double-upgraded observational studies High
Downgraded randomized trials; or upgraded observational studies Moderate
Double downgraded randomized trials; or observational studies Low
Triple downgraded randomized trials; or downgraded observa-
tional studies, or case series/case reports
Very low
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Copy of Table 12.2.a from Schünemann 2011
GRADE: Grades of Recommendation, Assessment, Development and Evaluation
Table 2. Factors that may decrease the quality level of a body of evidence
1. Limitations in the design and implementation of available studies suggesting high likelihood of bias
2. Indirectness of evidence (indirect population, intervention, control, outcomes)
3. Unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses)
4. Imprecision of results (wide confidence intervals)
5. High probability of publication bias
Copy of Table 12.2.b from Schünemann 2011
Table 3. Factors that may increase the quality level of a body of evidence
1. Large magnitude of effect
2. All plausible confounding would reduce a demonstrated effect or suggest a spurious effect when results show no effect
3. Dose-response gradient
Copy of Table 12.2.c from Schünemann 2011
Table 4. Studies not eligible for the synthesis
Study name Eisenburg 1984
Methods Randomised, double blinded, placebo-controlled trial
Cross-over trial with 3-week washout
Participants • 9 participants randomised (5 intervention, 4 control)
• Age range of participants: 10 to 42 years. Information on recruitment provided in the paper suggests that at
least three participants were under 18 years of age (“3 subjects came from two different special education schools
and were living with their parents” (p 144)
• Gender of participants: “Three subjects were girls” (p 144)
Interventions Intervention group
• Vasopressin (40 µg daily for 10 days)
Control group
• Placebo
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Table 4. Studies not eligible for the synthesis (Continued)
Outcomes Authors were unable to provide data separately for those participants that were over 18 years of age (ages ranged
from 10 to 42 years old and so the following summary concerned all participants). Only data on cognitive tests was
presented in the paper
Cognitive abilities
Performance on the Visual Verbal Paired Associate (VVPA) learning task improved more in the intervention group
(mean change 16%, SD 13%) than in those in the placebo group (mean change 7.4%, SD 12%), but this was not
statistically significant (t = 1.3, df = 16, P value = 0.11). Two of the 9 participants could not learn the word list at all.
Of the seven who could, there was no improvement with the drug (mean improvement 4.5%, SD 5%) compared
to placebo (mean improvement 6.8%, SD 9%)
Notes We contacted the authors of this study to request data for participants aged 18 to 42 years only. The author replied
stating that it would not be possible to access any information beyond what was available in the published paper
df - degrees of freedom
SD - standard deviation
A P P E N D I C E S
Appendix 1. Search strategies
1. Cochrane Central Register of Controlled Trials (CENTRAL, which includes the Specialised Register of the
Cochrane Developmental, Psychosocial and Learning Problems Group)
CENTRAL, part of the Cochrane Library, 2014, Issue 12. Searched 21 January 2015 [46 records]
#1 MeSH descriptor: [Dementia] explode all trees
#2 MeSH descriptor: [Cognition Disorders] explode all trees
#3 MeSH descriptor: [Delirium, Dementia, Amnestic, Cognitive Disorders] this term only
#4 ((cognit* or cerebr*) near/3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function*))
#5 (dementia or demented)
#6 MeSH descriptor: [Memory] this term only
#7 MeSH descriptor: [Memory Disorders] explode all trees
#8 (memory near/3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function* or loss*))
#9 MeSH descriptor: [Confusion] this term only
#10 (forgetful* or confused or confusion)
#11 Alz*eimer*
#12 Huntington*
#13 Lewy next bod*
#14 Creutzfeldt next Jakob or CJD
#15 MeSH descriptor: [Delirium] this term only
#16 deliri*
#17 {or #1-#16}
#18 MeSH descriptor: [Down Syndrome] this term only
#19 down* next syndrome
#20 downs next disease
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#21 trisomy next 21
#22 chromosome next 21
#23 (mongol or mongols or mongoloid or mongolism)
#24 {or #18-#23}
#25 #17 and #24 in Trials
2. ALOIS: Specialised register of the Cochrane Dementia and Cognitive Improvement Group
This register covers a number of sources, including the major bibliographic healthcare databases and trials register. To find out more
see: About ALOIS.
ALOIS. Up to date as of 1 January 2015. Searched 21 January 2015 [10 records]
“down* syndrome” OR “down* disease” OR “trisomy 21” OR “chromosome 21” OR mongol or mongoloid OR mongolism
3. Ovid MEDLINE(R)
Ovid MEDLINE 1946 to January Week 2 2015. Searched 20 January 2015 [477 records]
1 exp Dementia/
2 exp cognition disorders/
3 Delirium, Dementia, Amnestic, Cognitive Disorders/
4 ((cognit$ or cerebr$) adj3 (declin$ or deteriorat$ or degenerat$ or disorder$ or impair$ or function$)).tw.
5 alz?eimer$.tw.
6 (dementia or demented).tw.
7 huntington$.tw.
8 Lewy bod$.tw.
9 (Creutzfeldt-Jakob or cjd).tw.
10 Memory/
11 memory disorders/
12 Confusion/
13 (memory adj3 (declin$ or deteriorat$ or degenerat$ or disorder$ or impair$ or function$ or loss$)).tw.
14 (forgetful$ or confused or confusion).tw.
15 Delirium/
16 deliri$.tw.
17 or/1-16
18 Down Syndrome/
19 (down$ adj syndrome).tw.
20 Downs disease.tw.
21 trisomy 21.tw.
22 chromosome 21.tw.
23 (mongol or mongols or mongoloid or mongolism).tw.
24 or/18-23
25 randomized controlled trial.pt.
26 controlled clinical trial.pt.
27 randomi#ed.ab.
28 placebo$.ab.
29 drug therapy.fs.
30 randomly.ab.
31 trial.ab.
32 groups.ab.
33 or/25-32
34 exp animals/ not humans.sh.
35 33 not 34
36 17 and 24 and 35
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4. Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations. January 19, 2015. Searched 20 January 2015 [47 records]
1 ((cognit$ or cerebr$) adj3 (declin$ or deteriorat$ or degenerat$ or disorder$ or impair$ or function$)).mp.
2 alz?eimer$.mp.
3 (dementia or demented).mp.
4 huntington$.mp.
5 Lewy bod$.mp.
6 (Creutzfeldt-Jakob or cjd).mp.
7 (memory adj3 (declin$ or deteriorat$ or degenerat$ or disorder$ or impair$ or function$ or loss$)).mp.
8 (forgetful$ or confused or confusion).mp.
9 deliri$.mp.
10 or/1-9
11 (down$ adj syndrome).mp.
12 trisomy 21.mp.
13 chromosome 21.mp.
14 (mongol or mongols or mongoloid or mongolism).mp.
15 downs disease.mp.
16 or/11-15
17 (random$ or trial$ or control$ or group$ or blind$ or placebo$ or prospective).mp.
18 10 and 16 and 17
5. Embase (Ovid)
EMBASE 1974 to 2015 Week 3. Searched 20 January 2015 [548 records]
1 exp Dementia/
2 exp memory disorder/
3 memory/
4 exp confusion/
5 cognitive defect/
6 ((cognit$ or cerebr$) adj3 (declin$ or deteriorat$ or degenerat$ or disorder$ or impair$ or function$)).tw.
7 (memory adj3 (declin$ or deteriorat$ or degenerat$ or disorder$ or impair$ or function$ or loss$)).tw.
8 (forgetful$ or confused or confusion).tw.
9 (dementia or demented).tw.
10 Huntington$.tw.
11 Alz?eimer$.tw.
12 Lewy bod$.tw.
13 (Creutzfeldt-Jakob or cjd).tw.
14 delirium/
15 deliri$.tw.
16 or/1-15
17 Down syndrome/
18 (down$ adj syndrome).tw.
19 Downs disease.tw.
20 trisomy 21.tw.
21 chromosome 21.tw.
22 (mongol or mongols or mongoloid or mongolism).tw.
23 or/17-22
24 16 and 23
25 Randomized controlled trial/
26 controlled clinical trial/
27 Single blind procedure/
28 Double blind procedure/
29 triple blind procedure/
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30 Crossover procedure/
31 (crossover or cross-over).tw.
32 ((singl$ or doubl$ or tripl$ or trebl$) adj1 (blind$ or mask$)).tw.
33 Placebo/
34 placebo.tw.
35 prospective.tw.
36 factorial$.tw.
37 random$.tw.
38 assign$.ab.
39 allocat$.tw.
40 volunteer$.ab.
41 groups$.ab.
42 or/25-41
43 24 and 42
44 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
45 human/ or normal human/ or human cell/
46 44 and 45
47 44 not 46
48 43 not 47
6. PsycINFO (OVID)
PsycINFO 1806 to January Week 2 2015. Searched 20 January 2015 [76 records]
1 exp dementia/
2 cognitive impairment/
3 exp memory disorders/
4 memory/
5 delirium/
6 mental confusion/
7 Huntingtons Disease/
8 delirium/
9 ((cognit$ or cerebr$) adj3 (declin$ or deteriorat$ or degenerat$ or disorder$ or impair$ or function$)).tw.
10 (memory adj3 (declin$ or deteriorat$ or degenerat$ or disorder$ or impair$ or function$ or loss$)).tw.
11 (forgetful$ or confused or confusion).tw.
12 (dementia or demented).tw.
13 Huntington$.tw.
14 Lewy Bod$.tw.
15 (Creutzfeldt-Jakob or cjd).tw.
16 Alz?eimer$.tw.
17 or/1-16
18 down’s syndrome/
19 (down$ adj syndrome).tw.
20 Downs disease.tw.
21 trisomy 21.tw.
22 chromosome 21.tw.
23 (mongol or mongols or mongoloid or mongolism).tw.
24 or/18-23
25 17 and 24
26 clinical trials/
27 random$.tw.
28 (allocat$ or assign$).tw.
29 ((clinic$ or control$) adj trial$).tw.
30 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
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31 (crossover$ or “cross over$”).tw.
32 random sampling/
33 Experiment Controls/
34 Placebo/
35 placebo$.tw.
36 exp program evaluation/
37 treatment effectiveness evaluation/
38 ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
39 exp experimental methods/
40 or/26-39
41 25 and 40
7. CINAHL (EBSCOhost)
CINAHL 1937 to current. Searched 20 January 2015 [106 records]
S38 S22 AND S37
S37 S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36
S36 (MH “Treatment Outcomes”)
S35 (MH “Program Evaluation”)
S34 (MH “Quantitative Studies”)
S33 TX(“cross over”)
S32 TX (clinic* n1 trial*)
S31 PT Clinical trial
S30 TX placebo*
S29 (MH “Placebos”)
S28 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S27 TX (randomi* control* trial*)
S26 TX (random* N3 (allocat* or assign*))
S25 (MH “Meta Analysis”)
S24 (MH “random assignment”)
S23 (MH “Clinical Trials+”)
S22 S14 AND S21
S21 S15 OR S16 OR S17 OR S18 OR S19 OR S20
S20 mongol*
S19 chromosome 21
S18 trisomy 21
S17 Downs disease
S16 Down* syndrome
S15 (MH “Down Syndrome”)
S14 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S13 (memory N3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function* or loss*))
S12 ((cognit* or cerebr*) N3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function*))
S11 (forgetful* or confused or confusion or deliri*)
S10 (Creutzfeldt-Jakob or cjd)
S9 Lewy bod*
S8 Huntington*
S7 Alz*eimer*
S6 (MH “Memory Disorders+”)
S5 (MH “Memory”)
S4 (MH “Confusion+”)
S3 (MH “Delirium, Dementia, Amnestic, Cognitive Disorders”)
S2 (MH “Cognition Disorders+”)
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S1 (MH “Dementia+”)
8 to 11. Science Citation Index (SCI), Social Sciences Citation Index (SSCI), Conference Proceedings Citation
Index-Science (CPCI-S) (Web of Science), Conference Proceedings Citation Index-Social Science &
Humanities (CPCI-SS&H)
SCI 1970 to 20 January 2015. Searched 21 January 2015 [219 records]
SSCI 1970 to 20 January 2015. Searched 21 January 2015 [50 records]
CPCI-S 1990 to 20 January 2015. Searched 21 January 2015 [10 records]
CPCI-SS&H 1990 to 20 January 2015. Searched 21 January 2015 [1 record]
#20 #19 AND #13
DocType=All document types; Language=All languages;
#19 #18 OR #17 OR #16 OR #15 OR #14
DocType=All document types; Language=All languages;
#18 TS=(control* NEAR/1 trial*)
DocType=All document types; Language=All languages;
#17 TS=(placebo* )
DocType=All document types; Language=All languages;
#16 TS=(single or double NEAR/1 (blind*))
DocType=All document types; Language=All languages;
#15 TS=RCT
DocType=All document types; Language=All languages;
#14 TS=(random* NEAR/1 (trial or allocat* or assign*))
DocType=All document types; Language=All languages;
#13 #12 AND #7
DocType=All document types; Language=All languages;
#12 #11 OR #10 OR #9 OR #8
DocType=All document types; Language=All languages;
#11 TS=(“chromosome 21”)
DocType=All document types; Language=All languages;
#10 TS=(“trisomy 21”)
DocType=All document types; Language=All languages;
#9 TS=(mongol or mongols or mongoloid or mongolism)
DocType=All document types; Language=All languages;
#8 TS=( “down* syndrome” or “downs disease” )
DocType=All document types; Language=All languages;
#7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
DocType=All document types; Language=All languages;
#6 TS=(Alz*eimer* or Huntington* or CJD or “Creutzfeld Jacob” or “Lewy bod*”)
DocType=All document types; Language=All languages;
#5 TS=(deliri*)
DocType=All document types; Language=All languages;
#4 TS=((cognit* or cerebr*) near/3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function*))
DocType=All document types; Language=All languages;
#3 TS=(memory near/3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function* or loss*))
DocType=All document types; Language=All languages;
#2 TS= (forgetful* or confused or confusion)
DocType=All document types; Language=All languages;
#1 TS=(dementia or demented)
DocType=All document types; Language=All languages;
12. Cochrane Database of Systematic Reviews (CDSR)
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CDSR, part of the Cochrane Library, 2015, Issue 1. Searched 21 January 2015 [5 records]
#1 MeSH descriptor: [Dementia] explode all trees
#2 MeSH descriptor: [Cognition Disorders] explode all trees
#3 MeSH descriptor: [Delirium, Dementia, Amnestic, Cognitive Disorders] this term only
#4 ((cognit* or cerebr*) near/3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function*)):ti,ab,kw
#5 (dementia or demented):ti,ab,kw
#6 MeSH descriptor: [Memory] this term only
#7 MeSH descriptor: [Memory Disorders] explode all trees
#8 (memory near/3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function* or loss*)):ti,ab,kw
#9 MeSH descriptor: [Confusion] this term only
#10 (forgetful* or confused or confusion):ti,ab,kw
#11 Alz*eimer*:ti,ab,kw
#12 Huntington*:ti,ab,kw
#13 (Lewy next bod*):ti,ab,kw
#14 (Creutzfeldt next Jakob or CJD):ti,ab,kw
#15 MeSH descriptor: [Delirium] this term only
#16 deliri*:ti,ab,kw
#17 {or #1-#16}
#18 MeSH descriptor: [Down Syndrome] this term only
#19 (down* next syndrome):ti,ab,kw
#20 (downs next disease):ti,ab,kw
#21 (trisomy next 21):ti,ab,kw
#22 (chromosome next 21):ti,ab,kw
#23 (mongol or mongols or mongoloid or mongolism):ti,ab,kw
#24 {or #18-#23}
#25 #17 and #24 in Cochrane Reviews (Reviews and Protocols)
13. Database of Abstracts of Reviews of Effects (DARE)
DARE, part of the Cochrane Library, 2014, Issue 4. Searched 21 January 2015 [1 record]
#1 MeSH descriptor: [Dementia] explode all trees
#2 MeSH descriptor: [Cognition Disorders] explode all trees
#3 MeSH descriptor: [Delirium, Dementia, Amnestic, Cognitive Disorders] this term only
#4 ((cognit* or cerebr*) near/3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function*)):ti,ab,kw
#5 (dementia or demented):ti,ab,kw
#6 MeSH descriptor: [Memory] this term only
#7 MeSH descriptor: [Memory Disorders] explode all trees
#8 (memory near/3 (declin* or deteriorat* or degenerat* or disorder* or impair* or function* or loss*)):ti,ab,kw
#9 MeSH descriptor: [Confusion] this term only
#10 (forgetful* or confused or confusion):ti,ab,kw
#11 Alz*eimer*:ti,ab,kw
#12 Huntington*:ti,ab,kw
#13 (Lewy next bod*):ti,ab,kw
#14 (Creutzfeldt next Jakob or CJD):ti,ab,kw
#15 MeSH descriptor: [Delirium] this term only
#16 deliri*:ti,ab,kw
#17 {or #1-#16}
#18 MeSH descriptor: [Down Syndrome] this term only
#19 (down* next syndrome):ti,ab,kw
#20 (downs next disease):ti,ab,kw
#21 (trisomy next 21):ti,ab,kw
#22 (chromosome next 21):ti,ab,kw
#23 (mongol or mongols or mongoloid or mongolism):ti,ab,kw
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#24 {or #18-#23}
#25 #17 and #24 in Other Reviews
14. ClinicalTrials.gov
ClinicalTrials.gov
ClinicalTrials.gov. Searched 21 January 2015 [24 records]
Basic search: “Down syndrome” AND ( dementia OR Alzheimers OR cognition OR cognitive OR memory ) | Interventional Studies
15. World Health Organisation (WHO) International Clinical Trials Registry Platform (ICTRP)
apps.who.int/trialsearch/Default.aspx
ICTRP. Searched 21 January 2015 [22 records]
Standard search: down syndrome AND cognition OR down syndrome AND Alzheimers OR down syndrome AND dementia OR
down syndrome AND memory OR down syndrome AND cognitive
Appendix 2. Correspondence with pharmaceutical manufacturers
We contacted the following pharmaceutical manufacturers to request information about unpublished trial data.
1. Pfizer Ltd, the previous manufacturer for donepezil.
2. Eisai Co, Ltd the current manufacturer for donepezil.
3. Janssen-Cilag Ltd, the manufacturer of galantamine.
4. Lundbeck, the manufacturer of memantine.
5. Novartis, the manufacturer of rivastigmine.
6. t21 research society.
7. Jérôme Lejeune Foundation.
Appendix 3. Methods to be used in future updates of this review
Measures of treatment effect
We will extract both change scores (i.e. change from baseline) and final values. Studies with change-from-baseline outcomes will be
combined in a meta-analysis with studies with final measurement outcomes by using the (unstandardised) mean difference method in
RevMan (Review Manager 2012). We will present mean differences in change scores in one subgroup, mean differences in final values
in another, and pool both subgroups for an overall analysis (Higgins 2011).
We will only include data in the meta-analysis when it is at least approximately normally distributed. We will check the data for
skewness where possible by visual inspection of the histogram and calculating the observed mean minus the lowest possible value (or the
highest possible value minus the observed mean), and dividing this by the standard deviation (Higgins 2011). In the event that data are
identified as skewed, we will contact the study authors to request appropriate data summaries or acquisition of individual participant
data, in order to present results on a transformed scale, usually a log scale. If this is not possible, the results from these studies will be
presented narratively only.
Continuous data
When continuous outcome data are recorded using the same measurement scale, we will convert data into mean differences (MDs)
and present these with 95% confidence intervals (CIs).
Time-to-event data
We will convert time-to-event data (e.g. time to institutionalisation) into hazard ratios (HR) with 95% CIs.
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Multiple outcomes
When a study provides multiple, interchangeable continuous measures of the same construct at the same point in time (e.g. multiple
measures of behavioural problems), we will calculate the average SMD across these outcomes, and the average of their estimated
variances (Borenstein 2009). This will avoid the need to select a single measure, and any associated inflated precision in meta-analyses
(i.e. studies which report on more outcome measures will not receive more weight in an analysis than comparable studies, which report
on a single outcome measure). When a study provides multiple, interchangeable dichotomous measures of the same construct at the
same point in time, the same approach will be taken, this time averaging on the log OR (Higgins 2014 [pers comm]).
Economic issues
We will provide a narrative summary of any available data on the costs of programmes within the studies under review.
Unit of analysis issues
Cluster-randomised trials
Cluster-randomised trials are possible in this area, as allocation to the intervention group may occur by hospital or by community as
opposed to by individual participant. It is anticipated that should this occur, investigators will have controlled for a clustering effect
in their results already. If necessary, we will contact authors for further information. If study authors failed to control for a clustering
effect, we will request IPD in order to calculate an estimate of the intracluster correlation coefficient (ICC). If IPD are not available,
we will obtain an external estimate of the ICC from similar studies or available resources. If an appropriate ICC cannot be found from
any available resources, we will seek statistical advice to obtain an estimate of the ICC and use this to reanalyse the trial data to obtain
approximately correct analyses. This reanalysed trial data will then be entered into the RevMan software using the generic inverse
variance method to analyse effect sizes and CIs (Higgins 2011).
Cross-over trials
Cross-over trials are possible in this research area, as participants may receive both the control and intervention treatment but in a
different order. We will include relevant eligible cross-over trials in the review, but we will only use data gathered during the first period
of the study, up to the point of the first cross-over. This should avoid any problems associated with any carry-over effect from the first
period to the second period of the study.
Studies with multiple treatment groups
Studies with multiple intervention groups are possible in this area. If a study compares two or more eligible interventions groups to one
eligible control group, we will split the sample size for the shared comparator group evenly. This should prevent the same comparator
participants from being included twice. If a study compares one eligible intervention group to two or more eligible control groups, each
undergoing different yet equally eligible forms of ‘placebo’, we will combine the control groups to create a single pairwise comparison.
For dichotomous outcomes, both the sample sizes and the numbers of people with events can be summed across groups. For continuous
outcomes and time-to-event outcomes, means and standard deviations can be combined using methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011). If this strategy poses a problem for investigation of heterogeneity, we
will compare each group separately as part of the subgroup analyses (see Subgroup analysis and investigation of heterogeneity).
We will outline clearly in the review all decisions made regarding unit-of-analysis issues.
Dealing with missing data
We will contact authors and ask them to supply data missing from included studies. If this is not feasible, we will then follow the
recommendations of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Data that are missing are likely to be missing for reasons related to the outcomes of the missing data. For example, if a participant agrees
to take part in a trial, but experiences adverse events as a result of the medication, or fails to adhere to the medication throughout the
course of the study, he/she will be less likely to complete any follow-up assessments. We will apply an intention-to-treat analysis for all
missing data, and impute missing data wherever possible.
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When dichotomous data are judged not to be missing at random, we will assume that the participants experienced the less favourable
outcome (e.g. ’participant was institutionalised’), and we will impute the data accordingly.
We will impute missing continuous data and time-to-event data using a ’last observation carried forward’ (LOCF) approach, using
individual patient data (IPD) if available. Where this is not possible, we will impute sample mean values based on predicted values
from a regression analysis.
We will examine the impact on the results of changes in the assumptions made about missing data as part of the Sensitivity analysis. For
example, where dichotomous data cases are missing, we will impute data assuming that those missing experienced the positive outcome
(e.g. ’participant was not institutionalised’).
In the event of missing summary data, such as missing standard deviations, we will obtain these, where possible, using calculations
provided in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will specify themethods used to address anymissing data in the ’Characteristics of included studies’ tables. If insufficient information
is given regarding the exact number missing from each group, data imputation may not be possible, in which case, we will analyse only
the available data. If imputation is not possible, we will outline the reasons for this in the text. When imputation is not possible, the
results from these studies will be presented narratively.
Assessment of reporting biases
Wewill use visual inspections of funnel plots, along with trim and fill analyses, to assess publication and other reporting biases, providing
outcome data are available from a sufficient number of included studies (usually around 10). We will also use Egger’s regression intercept
(Egger 1997), and Begg’s rank correlation test to assess the asymmetry of the funnel plots (Begg 1994). Funnel plot asymmetry may
be due to publication bias or be attributable to a real relationship between trial size and effect size (e.g. when larger trials have lower
compliance, and compliance is positively related to effect size). In the event that we find such a relationship, we will examine clinical
variation of the studies (Higgins 2008; section 10.4). As a direct test for publication bias, we will compare results extracted from
published journal reports with results obtained from other sources (including correspondence).
Data synthesis
For some analyses, it may be necessary to incorporate IPD. In this event, we will use the IPD to generate estimates of effectiveness
(aggregate data) for each study separately and then combine these summary statistics using a two-stage approach (Stewart 2015).
Any IPD that are used in the data synthesis will be subject to data checking (such as adequate randomisation, selective outcome
reporting, and completeness of follow-up) by contacting the original study authors with open-ended questions about their study design
and conduct, as recommended by the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011; section 8.3.4).
Subgroup analysis and investigation of heterogeneity
Providing that there is a sufficient number of studies, subgroup analyses will examine the differential effects of:
1. the different types of pharmacological intervention (e.g. donepezil versus galantamine);
2. baseline cognitive functioning (mild-to-moderate intellectual disability at baseline versus moderate-to-severe intellectual
disability at baseline versus diagnosis of dementia at baseline);
3. interventions by stage of dementia (e.g. mild versus moderate versus severe); and
4. interventions by the age of the participant (e.g. young adults (18 to 30 years) versus mature adults (31 to 50 years) versus older
adults (50 years plus).
Sensitivity analysis
We will assess whether the findings of this review are robust to the decisions made in the process of obtaining them through the use of
sensitivity analysis. We will perform sensitivity analyses by conducting the following reanalyses:
1. excluding studies with issues regarding their study quality, excluding those with high risk of bias, or high attrition and dropout
rate;
2. without imputing data for the missing participants; and
3. using alternative outcomes from studies providing multiple measures of the same construct.
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H I S T O R Y
Protocol first published: Issue 2, 2015
Review first published: Issue 10, 2015
Date Event Description
4 September 2015 Amended This is an amended version of a previously published protocol. The scope of the review has been
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